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The growing prevalence of obesity has resulted in a huge impact on global 
health. Obesity contributes to the development of cardiovascular diseases, insulin 
resistance (IR) and other comorbidities. Research over the past few decades has 
revealed important roles for adipose tissue (AT) in regulating whole-body metabolism 
under normal physiological and pathological states. It is well accepted that obesity-
mediated chronic, low-grade inflammation contributes to the development of metabolic 
dysfunctions via the mitogen-activated protein kinase (MAPK) signaling pathways. While 
the upstream activation of MAPKs has been extensively investigated, how MAPK 
deactivation modulates cellular responses remains largely unsolved. In recent years, 
increasing attention has been given to the MAPK-specific, dual-specificity phosphatases 
(DUSPs) as key regulators that negatively control MAPK activity, potentially provide 
treatment against obesity-induced AT inflammation and IR.  
Early evidence has suggested a role for DUSP4 towards MAPKs signaling in other 
cell types. However, no study has addressed the role of DUSP4 in 3T3-L1 adipocytes 
under any condition. Data presented in this dissertation demonstrate that DUSP4 was 
induced via the MEK/ERK signaling pathway while JNK or p38 did not affect DUSP4 
expression. Subsequently, we show that DUSP4 protein was also stabilized by ERK 
activation and proteasomal activity was partially involved in its protein degradation. 
Moreover, the accumulation of DUSP4 correlated with the suppression of nuclear ERK 
signal and protein-protein interactions were observed between DUSP4 and ERK, 
suggesting a role for this phosphatase in spatiotemporal regulation of ERK activity in 
adipocytes.   
We further demonstrate that DUSP4 is suppressed in AT under conditions of 
genetic and diet-induced obesity that is associated with increased inflammation and IR. 
We report biphasic inductions of DUSP4 during adipocyte differentiation, with the early 
phase induction being ERK-dependent and the later phase induction being ERK-
independent and differentiation-specific. Moreover, DUSP4 was suppressed in 
preadipocytes and adipocytes exposed to tumor necrosis factor-α. Additionally, DUSP4 
knockdown did not inhibit adipocyte differentiation, suggesting a role for this 
phosphatase that is independent from adipogenesis. Collectively, data presented in this 
dissertation provide new insights into regulation and potential function of DUSP4 in 
adipocytes, highlighting new therapeutic targets for the treatment of obesity-mediated 
inflammation and metabolic disorders.
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CHAPTER I 
 
INTRODUCTION 
 
 
Significance of Research 
 
Obesity is the most prevalent nutrition-related health concern that leads to the 
development of many chronic diseases, such as cardiovascular disease, hypertension, 
cancers, and insulin resistance (IR). Globally, over 600 million people are obese. Obesity 
also contributes to the development of diabetes, and the rates are expected to increase 
from 415 million to 642 million between 2015 and 2040. As obesity and diabetes greatly 
threaten health care spending and economy growth, advanced therapeutic strategies 
against these diseases will be very important for our future generations. Early evidence 
has demonstrated that obesity-induced inflammation leads to IR, a key etiological factor 
for type 2 diabetes mellitus (T2D). Since then, numerous studies have established a 
pivotal role for the mitogen-activated protein kinases (MAPKs) in modulating obesity-
induced IR due to inflammatory stress response mediated through MAPK signaling 
pathways. While studies have largely examined upstream signaling for MAPK activation, 
few have addressed how MAPK deactivation alters biological outcomes, which could 
potentially provide novel targets against obesity-associated metabolic diseases. The 
MAPK-specific Dual-specificity phosphatases (DUSPs) are known to negatively regulate   
MAPK signaling. Although early studies have investigated the role of DUSPs in various
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types, information regarding the regulation and function of these DUSPs, especially 
DUSP4 in adipocytes remains limited. Collectively, the proposed research is significant, 
as it establishes novel mechanisms that characterize functional significance of DUSP4 in 
adipocytes, providing a platform for the development of potential therapeutic strategies 
against obesity-associated IR. The objective of this dissertation is to determine the 
regulation and mechanistic role of DUSP4 in 3T3-L1 adipocytes under conditions of 
agonist-specific MAPK activation, obesity-mediated inflammation and differentiation. 
The literature relevant to this research project is reviewed below. 
 
Review of Literature 
 
Obesity and Diabetes. Obesity is defined as excessive fat accumulation occurs to 
an extent that affect an individual’s health conditions. The prevalence of obesity and 
overweight has been increasing at an alarming rate worldwide, with the number rising 
from 857 million in 1980 to 1.9 billion in 2014 [1-3]. It is a major risk factor for the 
development of many chronic diseases, such as cardiovascular disease, hypertension, 
stroke, cancers, arthritis, IR and diabetes [1-6]. In addition to these serious health 
consequences, obese individuals have been reported to have an impaired quality of life 
and shortened life expectancy by up to 8 years [2, 6]. The World Health Organization 
(WHO) lists obesity as one of the five leading causes of mortality in the world [7]. While 
the onset and development of obesity have been attributed to genetics, ethnicity, 
culture and socioeconomic status, it is generally accepted that excess energy intake and 
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inadequate physical activity together contribute to the expansion of adipose tissue (AT) 
[8, 9]. According to the Centers for Disease Control and Prevention (CDC), in the United 
States, more than 70% of adults aged 20 or older are overweight and almost 37% are 
clinically obese or having a body mass index (BMI) of 30 kg/m2 or higher [10, 11].  
Meanwhile, the estimated annual health care costs of obesity-related illness are a 
staggering $190.2 billion, which accounts for more than 20% of annual medical spending 
in the United States [12]. Researchers have further projected that by 2030, if obesity 
rates continue to increase, obesity-associated medical costs will rise by $48 to $66 
billion a year in the U.S [13]. 
Similar to obesity, diabetes is another major health problem that affects an 
individual’s quality of life, decreases life expectancy and increases health care spending. 
Diabetes refers to a group of chronic metabolic diseases characterized by high levels of 
blood glucose resulting from defects in insulin production, insulin response or both [14, 
15]. The global epidemic of obesity has been shown to largely contribute to the rapid 
increase in the prevalence of diabetes [14, 16]. The number of adults with diabetes 
worldwide has quadrupled from 108 million in 1980 to 422 million in 2014, and this 
number is still expected to reach 642 million by 2040 [17-19]. The growing prevalence of 
diabetes is also associated with increased incidence of cardiovascular diseases, stroke, 
kidney failure, neuropathy and amputation. In the U.S., prevalence estimate from CDC 
concluded that approximately 29.1 million Americans are affected by diabetes (i.e., 
fasting blood glucose (FBG) > 126 mg/dL), while another 86 million have prediabetes 
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(i.e., FBG > 126 mg/dL) [20, 21]. Among those diabetic patients, T2D accounts for 90-
95% of all diagnosed cases [22, 23]. The estimated annual diabetes-related medical 
costs have risen to $332 billion and is projected to reach $490 billion by 2030 [24].  
These statistics clearly indicate that obesity and diabetes are major causes of 
morbidity and mortality and place a tremendous burden on the health care system. 
Whereas these diseases were once considered as health problems of adults, becoming 
more prevalent with aging, they have now become health problems among children, 
due to the increased incidence in childhood obesity [25, 26]. Therefore, reversing the 
epidemic of obesity and diabetes is of utmost important. Increased knowledge 
concerning mechanisms involved in the modulation of obesity-induced IR will become 
crucial for disease prevention and treatment for our future generations.  
Adipose Tissue as an Endocrine Organ. Obesity is the consequence of unhealthy 
and excessive AT expansion. AT is a highly innervated and complex organ that is mainly 
composed of mature adipocytes (ADs), preadipocytes (PAs) and various types of other 
cells, including fibroblasts, macrophages, endothelial cells, nerve cells, smooth muscle 
cells and lymphocytes [27, 28]. Historically, AT is mostly recognized as a depot in human 
body to store extra energy in the form of triglycerides during food abundance, and to 
release free fatty acids as energy supply in times of starvation for survival. Another 
function of AT is to act as an insulating layer that helps the body to maintain its core 
temperature. In addition, AT also provides protective padding and support around 
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major inner organs [27, 29, 30]. For centuries, obesity was even regarded as a sign of 
well-being or a symbol of higher social status by many societies [27].  
Since the beginning of twentieth century, the biology and functionality of AT 
started to draw growing attention, with accumulating evidence demonstrating that AT 
has a much more complex function beyond a repository for storing excess energy. A 
German doctor first suggested a role for AT in glycogen storage in 1905 [27]. Research 
conducted in the late 1980s identified AT as a major site of metabolism for sex 
hormones and secretion of adipsin, an endocrine factor found to be significantly 
suppressed with the development of obesity [31, 32]. A few years later, the 
identification and characterization of leptin, a hormone predominantly produced in AT 
that regulates whole-body energy homeostasis, led to the confirmation of AT as an 
active endocrine organ [33]. It is now well-recognized that AT expresses and secretes a 
variety of peptides, hormones, growth factors, cytokines and other biologically active 
molecules [34]. The production of each molecule is precisely controlled and this balance 
allows AT to regulate energy metabolism, immunity and vascular homeostasis in tissues 
such as liver, muscle, kidney and heart [27-30, 35]. While a number of factors have been 
found to affect AT function and trigger IR, abnormal expression of pro-inflammatory 
genes has been clearly identified as a crucial event coupling obesity to IR. 
Inflammation, Obesity and Insulin Resistance. Numerous studies over the past 
two decades have linked inflammation within AT to IR and subsequently T2D. Unlike 
acute inflammation that occurs quickly in response to a body injury and typically induces 
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pain and swelling, inflammation associated with obesity is a chronic, low-grade 
metabolic condition that can lead to insidious results. Evidence of the association 
between inflammation and IR can be dated back to over a century ago, however, the 
idea of IR and its role in the development of T2D was not well recognized due to 
inconclusive findings during that time [36]. A few decades later, several investigators 
reported that increased levels of inflammatory markers and mediators such as C-
reactive protein (CRP), interleukin-6 (IL-6), fibrinogen and plasminogen activator 
inhibitor-1 correlate with occurrence of T2D [37-41]. Treatment with a high-dose of the 
anti-inflammatory drug, sodium salicylate, ameliorated IR and improved glucose 
tolerance in type 2 diabetic patients [36, 42, 43]. These observations suggested that 
inflammation is highly involved in the pathogenesis of T2D. 
Prior to the identification of leptin, Hotamisligil and colleagues reported the first 
molecular evidence linking inflammation to obesity with the discovery that adipose-
tissue derived tumor necrosis factor-α (TNF-α), a pro-inflammatory cytokine, was 
overexpressed in AT of rodent model of obesity and had been shown to contribute to 
impaired insulin signaling [44]. These observations were revolutionary because it 
demonstrated for the first time that a molecule produced by expanding AT had systemic 
effect on metabolism. Since then, other studies reported elevated level of TNF-α in 
muscle and AT of obese patients, while weight loss intervention ameliorated circulating 
levels of TNF-α in the blood [45-47]. Administration of TNF-α has also been reported to 
suppress insulin sensitivity in models of animal and cell culture studies [48-50], whereas 
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deletion of TNF-α or its receptors improved insulin sensitivity in obese animals [51-53]. 
These observations clearly suggested an important role for TNF-α in linking obesity to IR. 
Interestingly, however, several other studies have reported that chronic TNF-α 
neutralization or administration of TNF-α antagonist does not improve insulin sensitivity 
in overweight subjects with metabolic syndrome and IR [54, 55], despite an observed 
improvement of inflammatory status [55]. The absent effect of TNF-α on insulin 
sensitivity may be due to a compensatory role of other inflammatory molecules 
produced by AT. In fact, since the initial identification of TNF-α, several other 
inflammatory mediators, such as MCP-1 and IL-6 have been shown to increase with 
obesity and contribute to the disruption of insulin signaling. 
Monocyte chemoattractant protein-1(MCP-1)/ Chemokine (C-C motif) ligand 2 
(CCL2) is a member of the C-C chemokine family. Since its discovery in 1989, MCP-1 has 
become one of the most extensively studied C-C chemokine, with interest in its role in 
the etiologies of obesity-related metabolic problems has grown exponentially over the 
past two decades [56-59]. MCP-1 acts as a potent chemotactic factor for migration and 
infiltration of monocytes/macrophages into AT [57]. Macrophage infiltration is a major 
determinant of AT inflammation, as this process leads to the production of other 
inflammatory molecules by macrophages [36, 57] (Fig.1.1). Similar to TNF-α, MCP-1 was 
also overexpressed in AT of animal and human obesity [59-61]. Weight loss significant 
reduced macrophage accumulation and inflammatory gene expression [60, 61]. When 
challenged with high fat diet, mice lacking MCP-1 or its cognate receptor CCR2 are 
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partially protected from IR due to decreased macrophage recruitment into AT, lower 
pro-inflammatory gene profile, improved insulin sensitivity and reduced susceptibility to 
obesity compared to their wild-type littermates [58, 62]. Similarly, systemic 
administration of MCP-1 in mice was shown to induce IR, and this adverse effect was 
attenuated by a CCR2 antagonist [62, 63]. Consistent with these observations, an in vitro 
study on 3T3-L1 ADs revealed that MCP-1 can disrupt insulin-stimulated glucose uptake 
and expression of key adipogenic genes [64]. Important findings from a more recent 
study revealed that other members of the C-C chemokine family, such as MCP-2, MCP-3, 
are also upregulated in animal models of diet and genetic-induced obesity [59]. 
Collectively, these results suggest that chemokines produced by AT may play a crucial 
role in the initiation of adipose inflammatory reactions that lead to IR. 
Inflammatory Signaling Pathways and IR. As obesity-mediated inflammation 
induces the production and secretion of inflammatory mediators in AT that contribute 
to the development of IR and T2D, identifying key inflammatory signaling pathways is 
important to our understanding of the root mechanisms involved in obesity-associated 
metabolic dysfunctions. Since the early 2000s, several studies have reported that the 
activity of two kinases, IκB-kinase β (IKKβ) and c-Jun N-terminal kinase (JNK), is elevated 
in metabolic tissues during obesity [65-68]. While IKKβ is a component of the nuclear 
factor kappa B (NF-κB) pathway and participate in the production of inflammatory 
cytokines via transcription factor NF-κB, JNK is a member of mitogen-activated protein 
kinase (MAPK) signaling pathway and capable of activating transcription factor AP-1 for 
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inflammatory cytokine production [36]. These two signaling pathways are activated in 
AT in response to inflammatory stress and lead to local IR (Fig.1.1). The produced 
inflammatory cytokines can continuously activate IKKβ and JNK, leading to a feed-
forward amplification mechanism [36, 68].  
Under normal physiological conditions, insulin first binds to its tyrosine kinase 
transmembrane receptor, inducing a conformational change of the receptor that leads 
to auto-phosphorylation on a number of tyrosine residues. The activated insulin 
receptor then mediates phosphorylation of selected tyrosine residues on members of 
the IRS family, such as IRS-1, IRS-2 and IRS-3. Tyrosine phosphorylated IRS-1, for 
example, then activates the phosphoinositide 3-kinase (PI3K/Akt) pathway, which 
stimulates translocation of glucose transporter 4 (GLUT 4) to the plasma membrane 
which subsequently increases glucose import into the cell [68, 69]. Under the 
pathological condition of IR, aberrant activation of MAPK signaling impacts cytosolic 
insulin signaling by phosphorylation of IRS-1 on its inhibitory serine site 307 (S307), 
leading to an inhibition of IRS-1 tyrosine phosphorylation, which further contributes to 
disrupted GLUT4 translocation and cellular glucose uptake [68, 70-72]. In addition, 
inflammatory signals mediated by MAPKs also directly influence RNA and protein 
synthesis of IRS-1 and GLUT4. 
MAPK Signaling Pathways, Obesity and IR. MAPKs are important mediators of 
signal transduction pathways and play a pivotal role in the regulation of many cellular 
processes including cell growth and proliferation, differentiation, migration, 
 
10 
 
inflammation and apoptosis, as well as other short-term hormonal changes required for 
homeostasis [73-76]. In mammalian cells, activation of MAPK signaling pathways is 
initiated by a variety of different stimuli, including growth factors, hormones, vasoactive 
peptides, cytokines and environmental stress factors such as ionizing radiation and 
osmotic shock [75, 77, 78]. As of today, most of the studies conducted to elucidate the 
function of MAPKs are focused on three major groups: extracellular signal-regulated 
kinases (ERKs), JNKs and p38 kinases [73-75, 77, 78] (Fig.1.2). It is generally accepted 
that ERK is activated by mitogens and growth factors and serves as an important 
regulator for cell cycle and proliferation. In contrast, JNK and p38 are activated by stress 
stimuli such as inflammatory cytokines, UV radiation and reactive oxygen species, and 
are associated with cellular stress and apoptosis [75, 77-80]. Therefore, JNK and p38 are 
also referred to as stress activated protein kinases [81]. All three MAPK signaling 
pathways are comprised of a three-tier kinase module (Fig.1.2A) in which a MAPK is 
activated upon phosphorylation by an upstream MAPK kinase (MAPKK), which is in turn 
activated when phosphorylated by a MAPKK kinase (MAPKKK) in response to 
extracellular stimuli [73-75, 77, 78].  MAPKs are dually phosphorylated by MAPKKs on 
tyrosine and threonine residues of a conserved Thr-X-Tyr motif within the kinase 
activation loop. Activation of MAPKs leads to the phosphorylation of numerous 
downstream target proteins and transcription factors within the cytosolic and nuclear 
compartments that further promote differential cellular outcomes. 
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The best characterized member of the MAPK family is ERK, which was first 
discovered over three decades ago for its ability to phosphorylate microtubule-
associated protein-2 (MAP-2) in 3T3-L1 ADs under treatment with insulin [80]. The ERK 
family is comprised the classical ERK1 and ERK2 (referred to as ERK1/2), and several 
other isoforms [77, 80]. While proteins encoded by ERK1/2 genes have molecular 
weights of 44 and 42 kDa, respectively, the other isoforms, such as ERK3, ERK5, ERK 7 
and ERK8, have relatively larger molecular weights ranging from 60kDa to 110 kDa [82, 
83]. All ERK family members contain a conserved TEY (Thr-Glu-Tyr) motif within the 
activation loop. ERK1/2 proteins are ubiquitously expressed, although their relative 
abundance varies in different tissues [73]. They are nearly 85% identical overall and 
share most of the signaling activities. However, they are not fully functionally redundant 
as demonstrated by gene knockout studies [84, 85]. Inactive ERK1/2 are reported to be 
sequestered by its upstream MAPKK, MAPK/ERK kinase 1 and 2 (MEK1/2), in the cytosol 
[86]. Phosphorylation of ERK leads to dissociation of the MEK-ERK complex and this 
activated ERK is then able to phosphorylate cytosolic and nuclear target proteins [77, 
86, 87]. As mentioned previously, ERK signaling is well known to be associated with cell 
survival and proliferation. Nevertheless, studies have also reported that, depending on 
stimulation and cell type, ERK may act in an opposite manner that leads to inflammation 
and apoptosis [88, 89]. 
A decade after the discovery of ERK, JNK was identified as a second member of 
the MAPKs for its ability to phosphorylate MAP-2 in rodent liver in response to injection 
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of protein synthesis inhibitor cycloheximide [90]. It was further reported that, following 
exposure to UV radiation, JNK was able to phosphorylate the transcription factor c-Jun 
on two serine residues within the N-terminal transactivation domain, thus increasing 
transcriptional activity of c-Jun [91, 92]. Since then, ten separate JNK isoforms have 
been identified as the products of three genes: JNK1/SAPKγ, JNK2/SAPKα, and 
JNK3/SAPKβ, with JNK1 and JNK2 each having two alternative splice sites and JNK3 
having one splice site [73, 77, 93]. All JNK isoforms contain a conserved TPY (Thr-Pro-
Tyr) motif within the activation loop and are more than 80% identical. While JNK1 and 
JNK2 are ubiquitously expressed, JNK3 is reported to be predominately found in tissues 
such as brain, heart and testis [94, 95]. Although the JNK isoforms may share functions 
in some circumstances, evidence from in vivo gene knock experiments has revealed 
specific roles for each isoform [96, 97]. In contrast to ERK activation, JNK is known to be 
directly and robustly phosphorylated by upstream MAPKK: MKK4 and MKK7, in response 
to inflammatory cytokines and cellular stress such as hyperosmolarity, heat shock, UV 
radiation, oxidative stress, and DNA damage [93, 98]. There is also evidence 
demonstrating JNK can be activated to a lesser extent by serum, growth factor, 
transforming agents, and other non-canonical signaling pathways [73, 77, 99].  
Around the same time that JNK was identified, another group of the MAPK 
family with a molecular weight of 38 kDa was discovered [73, 77]. p38α was the 
archetypal member of the p38 MAPK family reported simultaneously by three research 
groups In 1994 as 1) a tyrosine phosphorylated protein present in macrophages treated 
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with inflammatory cytokine LPS, 2) a molecule that binds to pyridinylimidazole drugs 
that block the production of pro-inflammatory cytokines, and 3) a reactivating kinase for 
MAP kinase-activated protein kinase -2 (MAPKAPK2) [100-103]. Since then, three other 
p38 isoforms have been identified, including p38β, p38γ, and p38δ [104-106]. All p38 
family members contain a conserved TGY (Thr-Gly-Tyr) motif within the activation loop 
and share over 60% structural similarity. While p38α and p38β are reported ubiquitously 
expressed, the other two isoforms have different tissue expression patterns, where 
p38γ is expressed primarily in skeletal muscle and p38δ is found in organs such as lung, 
kidney, pancreas, and small intestine [107]. MKK3 and MKK6 are the upstream MAPKK 
thought to be mainly responsible for p38 MAPKs activation. Similar to JNK, p38 can be 
activated in response to a number of stress stimuli including pro-inflammatory 
cytokines, heat and osmotic shock, UV radiation and oxidative stress [107].  
Over the past 15 years, a number of in vivo studies have been conducted to 
elucidate the mechanism of MAPK signaling in the development of obesity and IR. 
Evidence has revealed that, compare to wild type littermates, ERK 1 knockout mice were 
protected against diet-induced obesity and IR by mechanisms involving decreased 
adipogenesis and increased energy expenditure [79]. In contrast, mice lacking adapter 
p62, an ERK inhibitor, had increased ERK activity and developed mature-onset obesity 
and IR [108]. Increased activity of JNK is observed in liver, muscle, and AT during obesity 
[109]. Deletion of JNK in diet and genetic-induced rodent obesity led to decreased fat 
accumulation, less ADs formation, enhanced insulin receptor signaling, and improved 
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insulin sensitivity [110, 111]. Activity of p38 is also elevated in ADs isolated from T2D 
patients and involves in the suppression of GLUT4 expression [112]. Inhibition of p38 
improves glucose uptake [113]. Consistent with these findings, studies further report 
that both JNK and p38 can also translocate into the nucleus and activate other pro-
inflammatory genes, further promoting AT inflammation and IR [114, 115]. 
MAPK Signaling in Adipogenesis. Hyperplasia (cell number increase) and 
hypertrophy (cell size increase) are crucial mechanisms for the development of obesity, 
both of which are dependent on adipocyte differentiation [116]. Therefore, many 
research labs have extensively investigated the role of MAPKs in normal and 
pathological adipogenesis [117-123].  
The first molecular evidence linking ERK pathway to adipogenesis was published 
in 1991 when a group of scientists found that ectopic expression of an active Ras mutant 
led to growth arrest and terminal differentiation of 3T3-L1 PAs in the absence of insulin, 
while overexpression of an inactive Ras mutant suppressed differentiation [124]. Since 
the active form of Ras protein is a potent EKR pathway activator, these observations 
suggested a positive role for ERK in adipogenesis. A subsequent study using antisense 
technology against ERK also confirmed that ERK was required for 3T3-L1 adipocyte 
differentiation [121]. Nevertheless, other research groups had demonstrated that ERK 
could inhibit adipogenesis through suppressing the activity of peroxisome proliferator-
activated receptor γ (PPARγ), an transcription factor highly expressed in AT and 
considered a master regulator of adipocyte differentiation, by direct phosphorylation 
 
15 
 
[119, 125]. The hypothetical contradictory findings that ERK could both induce and 
suppress adipogenesis were built into a working model for temporal regulation of ERK. 
Supporting evidence later demonstrated that, upon adipogenic stimulation, ERK 
pathway was necessary for the early proliferative phase of differentiation, termed 
mitotic clonal expansion (MCE) [126]. Blockade of EKR activity with a specific and potent 
MEK-inhibitor, U0126, during MCE was shown to inhibit differentiation [126]. PPARγ was 
not detected during this proliferative phase, and was significantly induced during 
terminal differentiation of ADs. On the other hand, ERK activity returned to basal level 
during later stages of differentiation [120], which would be necessary to avoid negative 
impact towards PPARγ [79]. In addition, other studies have further demonstrated that 
ERK activity during MCE is necessary for inducing expression of key adipogenic 
transcription factors: C/EBPβ, C/EBPδ and C/EBPα [122, 127-129]. Collectively, these 
results indicate the importance of ERK signaling in adipogenesis. 
Similar to ERK, p38 activation is also required for adipocyte differentiation. The 
first positive role for p38 in adipogenesis was elucidated in 3T3-L1 cells in the late 1990s 
[120, 123]. Inhibition of p38 was found to suppress differentiation of PAs into mature 
ADs, which was attributed to a decrease in C/EBPβ phosphorylation and transactivation 
[123]. Furthermore, it was observed that overexpression of an active MKK6 mutant, an 
upstream activator of p38, was sufficient to induce adipocyte differentiation of 3T3-L1 
cells without any hormonal inducer [120]. However, persistent activation of p38 leads to  
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massive cell death [120], indicating p38 activation has differential effects depending on 
the stage of differentiation.  
To a lesser extent, JNK has also been reported to play a role in adipocyte 
differentiation Evidence indicates that PPARγ is phosphorylated by JNK and that this 
phosphorylation results in PPARγ protein degradation and a reduction in PPARγ-
dependent transcriptional activity [130]. Moreover, JNK activity is elevated in ADs 
during inflammatory stress, which triggers IRS-1 phosphorylation on S307 and decreases 
glucose uptake [70, 131, 132]. 
MAPK Phosphatases. An interesting feature of MAPK signaling is that the 
activation of a single MAPK signaling pathway leads to diverse cellular outcomes. With 
mounting evidence demonstrating that differences in the magnitude, duration, and 
subcellular localization of MAPK activities modulate cell signaling specificity (Fig.1.2B), 
the precise regulation of MAPK signaling is critical in determining various cellular 
physiological and pathological processes. As dual phosphorylation within the MAPK 
activation loop is required for MAPK activation, desphosphorylation of one or both 
residues leads to termination of MAPK activity.  
In mammalian cells, inactivation of all known MAPKs can be achieved by a group 
of phosphatases that remove phosphate groups from threonine and/or tyrosine 
residues within the MAPK activation loop [133, 134]. These phosphatases include 
protein tyrosine phosphatases (PTPs) (e.g. PTP-SL, and STEP), serine/threonine 
phosphatases (PPs) (e.g., PP2A, and PP2C) and dual-specificity phosphatases (DUSPs) 
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[133, 135-138]. While the first two subgroups of phosphatases dephosphorylate only 
single tyrosine or threonine residues on MAPKs, DUSPs dephosphorylate both tyrosine 
and threonine residues in the activation loop of MAPKs [133, 135, 138]. Because 
abnormal MAPK activities lead to adipocyte dysfunction and IR, numerous studies are 
underway to identify phosphatases involved in the regulation of MAPKs activity that 
contribute to the prevention and treatment of obesity-induced inflammation and 
metabolic dysfunction. Of these phosphatases, the DUSP family has recently emerged. 
DUSPs. Since DUSPs were first identified in the early 1990s, knowledge regarding 
molecular mechanisms and substrates of DUSPs has been emerging rapidly [139, 140]. 
More than 40 DUSPs have been identified so far, and at least 16 have displayed 
dephosphorylating activity towards MAPKs [135, 141, 142]. Ten of those 16 DUSPs have 
been documented to be MAPK-specific in mammalian cells. They are comprised of two 
domains, the C-terminal dual-specificity phosphatase domain (DSP) and the N-terminal 
CH2 MAPK-binding (MKB) domain (Fig.1.3A). Evidence shows that the MKB domain plays 
a critical role in regulating enzymatic specificity through docking interaction that helps 
individual phosphatases to determine binding specificity towards activated MAPK 
proteins [143, 144] (Fig.1.3B). The MKB domain also contains sequences that determine 
the subcellular localization of DUSPs. A number of studies have provided molecular 
evidence that several members of the DUSP family can be catalytically activated by 
substrate binding to its MKB domain, resulting in a conformational change of the 
phosphatase, thereby largely enhancing its catalytic activity.  
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The 10 MAPK-specific DUSPs can be further divided into three subfamilies based 
on their sequence homology, substrate specificity and localization (Fig.1.3A). Members 
identified in this first group includes DUSP1, DUSP2, DUSP4 and DUSP5. They localize 
exclusively to the nuclear compartment with a nuclear localization signal (NLS) sequence 
in the N-terminus and are induced by growth factors or stress signals that activate all 
three MAPKs. The second group is comprised of DUSP6, DUSP7 and DUSP9. These 
DUSPs localize predominantly in the cytoplasm due to a nuclear export signal (NES) 
sequence and preferentially target ERK1 and ERK2. The third group of DUSPs consists an 
extended region either in the N-terminus (e.g., DUSP10) or in the C-terminus (e.g., 
DUSP8, and DUSP16) in addition to the DSP and MKB domain. The extended C-terminus 
contains both the NLS and NES, allowing these members to be localized within the 
cytoplasmic and nuclear compartments. They are known to preferentially regulate the 
activity of JNK and p38 [134, 143-145]. In addition, group III phosphatases also contains 
PEST sequences that is known to be associated with protein turn over [146, 147]. Most 
members of these DUSPs display wide tissue distribution, however, some exhibit a more 
restricted expression pattern. For example, DUSP2 is found to be predominantly 
expressed in hematopoietic tissue [148], while DUSP8 is mainly expressed in tissues 
such as brain, eye, heart and lung [149, 150]. Expression of DUSP9 is detected in 
placenta, kidney and fetal liver [151], while DUSP10 reported to be restricted to skeletal 
muscle and liver [152].  
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DUSP4. One member of the MAPK-specific DUSPs that has gained increasing 
interest in the last few years is DUSP4, a phosphatase found to be expressed in a wide 
variety of tissues [153, 154]. Evidence from in vitro studies has revealed that DUSP4 can 
be induced by growth factors, oxidative stress, oncogenes, phorbol 12-myristate 13-
acetate (PMA), UV irradiation and LPS [155-159]. While DUSP1 is identified as an 
immediate-early nuclear inducible gene in response to extracellular stimulation, DUSP4 
exhibits a relatively late phase induction [160, 161]. Several studies have demonstrated 
that DUSP4 is localized to the nuclear compartment due to two distinct NLS’s and 
dephosphorylates either ERK or JNK, depending on cell type [158, 162, 163]. Unlike 
DUSP1 that only dephosphorylates and release ERK back to the cytosol, DUSP4 displays 
a higher binding affinity for ERK and retain this kinase in the nucleus, suggesting a more 
potential role in spatiotemporal regulation of ERK that could subsequently influence 
cellular outcomes [164]. Nevertheless, a couple of studies have provided contradictory 
findings on regulatory function of DUSP4 towards p38. One group reported that DUSP4 
did not dephosphorylate p38, but exhibited strong binding affinity towards this kinase 
[165], while the other observed that DUSP4 knockdown led to over-activated p38 under 
oxidative stress [166].  
Previous studies have demonstrated a role for DUSP4 in cancer, apoptosis and 
senescence. Evidence has linked DUSP4 to the development of oesophagogastric rib 
metastasis, ovarian cancers, liver carcinoma, and acute myeloid leukemia [167-170]. In 
contrast, others have identified DUSP4 as a tumor-suppressor gene with the observation 
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that the expression of DUSP4 is suppressed in primary breast cancer, prostate cancer, 
and lung cancer [171-173]. Overexpression of DUSP4 has been shown to negatively 
regulate JKN activity, and as a result, causes JNK-dependent apoptosis [163, 173]. In 
other cell types, expression of DUSP4, regulated by transcription factors p53 or E2F-1, 
has been shown to modulate H2O2-induced apoptosis by inactivating ERK [174, 175]. 
Furthermore, it suggested that ERK phosphorylation of DUSP4 on T361/T363 and 
S390/S395 residues highly stabilized this phosphatase from ubiquitin-associated 
degradation [156, 157]. Once being activated by ERK, DUSP4 could regulate cell 
senescence by inactivating nuclear ERK [176, 177].  
Interestingly, G2/M-phase growth arrest and enhanced cyclin B1 expression 
have been observed in embryonic fibroblasts (MEF) of DUSP4 knockout mice [159]. 
Similar results have also been obtained from mice mammary tumor cells using DUSP4 
siRNA [168]. This newly discovered feature of DUSP4 function is distinct from DUSP1, 
which is shown to be associated with the entry into cell cycle. It has been reported that 
DUSP4 appears to potentiate inflammation in response to LPS-mediated septic shock 
and acute lung injury [178, 179]. In contrast, another investigation has demonstrated a 
role for DUSP4 in protecting against intracellular infection by parasites in macrophages 
derived from DUSP4 knockout mice [180]. These findings support potential roles for 
DUSP4 in the regulation of cell cycle and in the response to inflammation.  
Although the MAPKs have been extensively studied in the regulation of insulin 
action and adipocyte functions, the role of DUSPs, especially DUSP4, on chronic, low-
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grade inflammation in the development of obesity-induced IR and subsequent T2D 
remains largely unknown. It was not until recently that a growing number of 
investigations have been conducted to better understand roles of DUSPs in adipocyte 
regarding MAPK signaling and insulin sensitivity [165, 181, 182]. For instance, DUSP1 is 
immediately induced during the early phase of adipocyte differentiation in response to 
hormonal inducers and its induction controls the magnitude and duration of ERK and 
p38 activity [161]. Genetic ablation of DUSP1 leads to prolonged ERK activation and 
inhibited adipocyte differentiation [182]. Expression of DUSP9 is induced during 
adipocyte differentiation. It has been reported that overexpression of DUSP9 in 3T3-L1 
cells suppressed ERK and JNK activation, leading to a recovery of insulin-mediated 
PI3K/Akt pathway and improved glucose uptake [181]. Interestingly, evidence suggests 
that DUSP4 suppresses gluconeogenesis. Under low energy states, AMP-activated kinase 
(AMPK) activates transcription factor Egr-1, which binds and induces DUSP4 expression, 
leading to dephosphorylation of p38 and repression of phosphoenolpyruvate 
carboxykinase (PEPCK) [165]. A recent macrophage-adipocyte co-culture study has 
provided evidence for the first time that DUSP4 ectopic expression in macrophages 
inhibits the production of inflammatory cytokines mediated by free fatty acid (FFA) and 
suppresses inflammatory activation of macrophages by reducing JNK and p38 activity 
[183]. In addition, overexpression of DUSP4 in macrophages also suppressed 
inflammation during macrophage-adipocyte interaction [183]. However, there is still a 
lack of understanding the molecular basis of DUSP4 in the development of obesity and 
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IR in ADs. As evidence above demonstrated potential the role of DUSP4 in regulating 
cell-cycle progress, apoptosis, gluconeogenesis, and inflammation in various cell types, it 
will be of great interest to elucidate the molecular role and physiological function of 
DUSP4 in regulation of obesity-mediated inflammation and metabolic disorder in ADs. 
 
Study Objectives 
 
Chapter II. Little is known regarding the regulatory mechanism and function of 
DUSP4 in adipocytes. Therefore, the objective of the study summarized in chapter II is to 
examine the regulation and function of DUSP4 in 3T3-L1 cultured adipocytes. We will 1) 
determine how DUSP4 is regulated in response to agonist-specific MAPK activation, 2) 
determine the mechanisms involved in DUSP4 protein stabilization and degradation, 
and 3) elucidate the potential role for DUSP4 in regulating ERK activity within specific 
cellular compartment. 
Chapter III. While others have studied the regulation of function of several 
DUSPs, including DUSP1 and DUSP9 with regards to obesity, inflammation and 
adipogenesis, a role for DUSP4 under these conditions remains unknown. Therefore, the 
objective of the study summarized in chapter III is to: 1) establish relative DUSP4 
expression in major insulin responsive tissues of lean mice, 2) examine how DUSP4 is 
regulated during the development of genetic and diet-induced mouse models of obesity 
as these animals transition to a more inflammatory state, 3) determine the regulation 
and role for DUSP4 in adipocyte differentiation.  
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Figure 1.1. Obesity-induced Adipose Tissue Inflammation. Obesity is 
characterized by expansion of adipose tissue (AT). As AT mass continues to 
expand, adipocytes can secrete chemoattractant proteins (i.e., MCP-1) to 
recruit macrophages into AT. Infiltrated macrophages and enlarged adipocytes 
secrete a large amount of inflammatory cytokines, including TNF-α and IL-6 that 
stimulates PAs and ADs to activate inflammatory signaling pathways (i.e., 
MAPK) and gene expression, leading adipocyte dysfunction and IR. 
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Figure 1.2. Overview of MAPK Signaling Pathways. 
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Figure 1.3. DUSPs Classification and Domain Structure.  
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CHAPTER II 
 
REGULATION OF ENDOGENOUS DUAL-SPECIFICITY PHOSPHATASE 4 BY AGONIST-
SPECIFIC MAPK ACTIVATION IN ADIPOCYTES 
 
 
Abstract 
 
Activation of the ERK, JNK and p38 mitogen activated protein kinases (MAPKs) by 
different extracellular stimuli leads to a variety of cellular outcomes, such as 
proliferation, inflammation, differentiation and apoptosis. The signal specificity is shown 
to be dependent upon duration, magnitude and localization of MAPK activity. While 
numerous studies have examined upstream signaling for MAPK activation, few have 
addressed how MAPK deactivation alters biological responses.  Evidence now supports 
potential roles for MAPK-specific, dual-specificity phosphatases (DUSPs) in the 
deactivation of MAPK signaling and modulation of obesity-associated metabolic 
dysfunction. However, the precise mechanisms underlying the regulation of DUSPs 
remain poorly understood. In this study, we have investigated regulatory mechanisms of 
endogenous DUSP4 by several MAPK agonists: tumor necrosis factor- (TNF-), 
hydrogen peroxide (H2O2), ultraviolet (UV) irradiation and phorbol 12-myristate 13-
acetate (PMA). We found that PMA stimulation resulted in robust and sustained ERK 
phosphorylation up to 8 hours, leading to a stronger induction of endogenous DUSP4. 
Treatment with the ERK inhibitor U0126 suppressed ERK phosphorylation and abolished  
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DUSP4 expression.  In contrast, TNF-, H2O2, and UV irradiation that led to transient ERK 
phosphorylation were not able to induce DUSP4 protein accumulation. In addition, 
PMA-mediated sustained ERK phosphorylation highly stabilized DUSP4 protein, while 
blocking ERK activity resulted in a much shortened DUSP4 half-life. Furthermore, we 
demonstrated that the induction of DUSP4 correlates with the loss of ERK activation in 
the nucleus while cytosolic ERK remains activated. Finally, protein-protein interactions 
were observed between DUSP4 and ERK. Collectively, these results demonstrate 1) 
induction of endogenous DUSP4 is tightly regulated by the duration and magnitude of 
ERK activity; 2) phospho-ERK is involved in DUSP4 protein stability; 3) DUSP4 only 
modulates ERK activity in a compartment-dependent manner as a nuclear phosphatase; 
and 4) DUSP4 serve as an anchor protein that retains ERK in the nucleus, preventing 
reactivation of this kinase by upstream kinases.    
Introduction 
 
Obesity is the result of excessive fat accumulation in the body due to an 
imbalance between caloric intake and energy expenditure[1]. It is the most prevalent 
nutrition-related health concern worldwide as it contributes to the increased risk of 
numerous chronic diseases, such as cardiovascular disease, hypertension, cancer, insulin 
resistance and type 2 diabetes [2-4]. Studies over the past three decades have 
demonstrated that obesity is associated with a progressive infiltration of macrophages 
that results in increased production of proinflammatory cytokines such as tumor 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which leads to chronic, low-grade 
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inflammation[3, 5, 6].  These inflammatory cytokines further contribute to the initiation 
and development of many metabolic disorders by aberrantly activating intracellular 
signaling molecules, such as the mitogen-activated protein kinases (MAPKs) [7, 8].  
MAPKs are important mediators of signal transduction pathways and play a 
pivotal role in the regulation of numerous cellular processes including cell growth and 
proliferation, differentiation, inflammation and apoptosis. Most of the functional 
studies of MAPKs are focused on three major groups: extracellular signal-regulated 
kinases (ERKs), c-Jun amino-terminal kinases (JNKs) and p38 kinases [9]. The MAPK 
signaling cascade is directed by sequential kinases activity, for instance, MAPK is 
phosphorylated by upstream MAPK kinases (MAPKKs), which are phosphorylated by 
MAPK kinase kinases (MAPKKKs) in response to diverse extracellular signals. Dual-
phosphorylation of tyrosine and threonine residues within the T-X-Y motif of the 
activation loop is required for MAPK activation, leading to the phosphorylation of 
cytosolic and nuclear targets [9, 10]. While MAPK activation by upstream signaling has 
been extensively investigated, mechanisms regarding MAPK deactivation are still poorly 
understood. Growing evidence now suggests that MAPK inactivation by phosphatases is 
also a critical event that modulates MAPK-associated biological consequences in 
response to extracellular signals [11-13]. A subgroup of the protein tyrosine 
phosphatases superfamily, known as the dual-specificity phosphatases (DUSPs), 
dephosphorylate both tyrosine and threonine residues of MAPKs [11, 14]. Within this 
group, 10 DUSPs share a common MAPK binding domain (MKB), allowing them to carry 
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out catalytic activity through docking interaction specifically towards MAPKs [11, 15, 16]. 
These MAPK-specific DUSPs can be further divided into three subgroups based on their 
sequence homology, substrate specificity and subcellular localization. The first group 
includes DUSP1, DUSP2, DUSP4 and DUSP5. They localize exclusively to the nuclear 
compartment with a nuclear localization signal (NLS) sequence and are induced by 
growth factors or stress signals that activate all three MAPKs. The second group, 
comprised of DUSP6, DUSP7 and DUSP9, are ERK-specific and localize predominantly in 
the cytoplasm with a nuclear export signal (NES) sequence. The third group contains 
DUSP8, DUSP10 and DUSP16, which are JNK/p38-specific and localized in both the 
cytoplasm and nucleus [11, 15-19].  
In recent years, there is growing interest in the role for DUSPs in adipocytes 
metabolism and obesity-mediated inflammation. For instance, genetic ablation of 
DUSP1 leads to prolonged ERK and p38 activation without any interference on adipocyte 
differentiation [20]. Overexpression of DUSP9 in 3T3-L1 cells suppressed ERK and JNK 
activation leading to improved glucose uptake under inflammatory stress [21]. DUSP4, 
one of the earliest DUSPs identified, is another candidate that has drawn attention for 
its role in regulation of MAPK signaling in numerous cell types. Evidence from in vitro 
studies show that DUSP4 can be induced by growth factors, oxidative stress, oncogenes, 
lipopolysaccharide (LPS) and UV radiation [22-25]. Others have shown that DUSP4 is 
localized in the nucleus due to two NLS and dephosphorylates either ERK or JNK, 
depending on cell type [22, 25, 26]. Studies also demonstrate potential roles for DUSP4 
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in regulating cell proliferation, inflammation, and gluconeogenesis in other cell types 
[23, 27, 28]. However, relatively little attention was given to its role in adipocytes. A 
recent study using macrophage-adipocyte co-culture revealed that ectopic DUSP4 
expression in macrophages inhibits production of inflammatory cytokines mediated 
under free fatty acid stimulation, and subsequently reduces JNK and p38 activity [29]. In 
addition, overexpression of DUSP4 in macrophages also suppressed inflammatory stress 
mediated by macrophages during macrophage-adipocyte interaction [29].  
Despite the potential biological function demonstrated by others, the regulatory 
mechanism of DUSP4 in adipocytes remains poorly understood. Since DUSP4 ectopic 
expression has been reported to artificially shift the balance of its subcellular localization 
[30], herein, we sought to elucidate the regulatory mechanisms of endogenous DUSP4 
by MAPK activity and subsequent spatiotemporal regulation of MAPK activity by DUSP4 
in adipocytes. We found that induction of endogenous DUSP4 requires strong and 
sustained ERK activation. We also demonstrated that ERK activation stabilizes DUSP4 
protein while blockade of ERK activity leads to rapid DUSP4 degradation mediated 
partially by proteasome activity. Moreover, we observed that DUSP4 was exclusively 
localized in the nucleus, and the accumulation of DUSP4 correlated with the suppression 
of nuclear ERK phosphorylation. Additionally, we revealed that DUSP4 co-
immunoprecipitated with ERK, suggesting an important role for DUSP4 in spatiotemporal 
regulation of nuclear ERK activation via negative feedback mechanism. 
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Materials and Methods 
 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
Trypsin-EDTA, and recombinant murine TNF-α were purchased from Invitrogen. Fetal 
bovine serum (FBS) was obtained from HyClone. The following antibodies were used for 
immunoblot analysis: phospho-MEK, phospho-ERK (Thr202/Tyr204), phospho-p38 
(Thr180/Tyr182), phospho-JNK (Thr183/Tyr185), total ERK and α-tubulin, were 
purchased from Cell Signaling; DUSP4 (SC-1200) were purchased from Santa Cruz 
Biotechnology. Pharmacological inhibitor of ERK (U0126) was purchased from 
CalBiochem. Epoxomicin was purchased from Boston Biochem. Cycloheximide was 
purchased from Sigma. Enhanced chemiluminescence (ECL) reagents were obtained 
from Perkin-Elmer Life Sciences. All TaqMan primer probes used in this study were 
purchased from Applied Biosystems. 
Cell Culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School. Cells were propagated in DMEM supplemented with 10% CS 
until reaching density-induced arrest, as previously described. Throughout the study, 
‘0h’ refers to density arrested cells immediately prior to stimulation as described in 
figure legend. Experiments described herein were conducted in density-arrested 
preadipocytes. All experiments were repeated 2- 3 times to validate results and ensure 
reliability. 
Immunoblotting. Cell monolayers were washed with phosphate-buffer saline 
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM NaCl, 
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10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 
1 mM EGTA. Phosphatase inhibitors (20 mM β-glycerophosphate, 10 mM sodium 
fluoride and 2 μM sodium orthovanadate) and protease inhibitors (0.3 μM aprotinin, 21 
μM leupetin, 1 μM pepstatin, 50 μM phenanthroline, 0.5 μM phenylmethylsulfonyl 
fluoride) were added to lysis buffer immediately prior to cell harvest. Cell lysates were 
sonicated and centrifuged (15,000g, 10 min, 4°C), and the supernatant transferred to a 
fresh tube. Protein content was determined by bicinchoninic acid (BCA) procedures 
according to manufacturer’s (Pierce, Rockford, IL) instructions. Equal amounts of whole 
cell lysate protein were separated by SDS-PAGE electrophoresis. Cell lysates were mixed 
with loading buffer containing 0.25M Tris (pH6.8), 4% SDS, 10% glycerol, 0.01% 
bromophenol blue, and 10% dithiothreitol, then heated at 80°C for 5 min prior to 
electrophoresis. Proteins were resolved on SDS-polyacylamide gel electrophoresis 
(PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore corp., 
Billerica, MA). After transfer, membranes were blocked with 4% milk and probed with 
indicated primary antibodies overnight at 4°C. Membranes were subsequently probed 
with horseradish peroxidase conjugated secondary antibodies for 2 hrs at room 
temperature. Membranes were immersed in ECL and data visualized by 
autoradiography using CL-XPosure film (Pierce).  
Real-Time RT-PCR. Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to 
manufacturer protocol. Total RNA was quantified with a Nanodrop ND-1000 
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spectrophotometer. Total RNA was reverse-transcribed to cDNA in a 10 μl reaction 
volume using a high capacity cDNA reverse transcription kit (Applied Biosystems). The 
reverse transcription (RT) master mix containing RT buffer, deoxyribonucleotide 
triphosphate (dNTP) mix, RT random primers, RNase inhibitor (1.0 U/μl), and MultiScribe 
RT was added to 1 μg RNA and RNase-free water. Reverse transcription reaction 
conditions followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, 
followed by 4°C in definitely/ RT complete) and utilized the Gene Amp PCR System 9700 
thermal cycler (Applied Biosystems) for cDNA synthesis. PCR amplification was run 
utilizing the 7500 fast system (Applied Biosystems) that consisted of enzyme activation 
at 95°C for 20 sec, followed by 40 cycles of denaturation at 95°C for 3 sec combined with 
annealing /extension at 60°C for 30 sec. All data were analyzed with the ABI 7500 real 
time PCR system. All TaqMan primer probes used in this study were also purchased 
from ABI. Data were recorded and analyzed with ABI Sequence Detector Software and 
graphs visualized with Excel software. All data were presented as mean ± standard error 
of the mean (SEM) and representative of duplicate determinations. Data were 
normalized to 18S and measured as relative differences using the 2-ΔΔCT method as 
previously described [31, 32]. 
Immunofluorescence. Cells, cultured in 4-well glass chamber slides (Nunc Lab-
Tek II System; Thermal Scientific Co.) at 37ºC overnight, were washed with PBS, fixed 
with methanol free 4% Formaldehyde (Polysciences) for 15 min at room temperature, 
permeabilized with 0.2% Triton X for 5 min, blocked with 10% BSA for 20 min, and 
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incubated overnight with primary antibody at 4°C. Cells were subsequently washed and 
incubated with fluorescently-conjugated secondary antibodies, Alexa Fluor® 488 anti-
mouse and Alexa Fluor® 594 anti-rabbit (Molecular Probes), in dark for 30 min at room 
temperature. Slides were then washed with PBS, mounted using Antifade mounting 
solution (Molecular Probes) and visualized by confocal microscopy. 
Immunoprecipitation/Co-immunoprecipitation. Co-immunoprecipitation (co-IP) 
was performed using the Thermo Fisher Scientific Pierce co-IP kit (26149) following the 
manufacturer's protocol. Briefly, total ERK and DUSP4 antibodies were first immobilized 
for 2 hrs using AminoLink Plus coupling resin. Cells were washed with PBS and incubated 
with IP Lysis/Wash buffer containing 25 mM Tris, pH 7.4, 150 mM NaCl, 1% NP40, 1 mM 
EDTA and 5% glycerol on ice. Cell lysates were collected by brief centrifugation (13,000g, 
10 mins, 4°C). The antibody-coupled resin was then washed and incubated with cell 
lysate at 4°C overnight. After incubation, the resin was again washed and protein 
complex eluted using elution buffer. Protein complexes were then resuspended in 
loading buffer, resolved on SDS-polyacrylamide electrophoresis gel, and immunoblotted 
as discussed above. 
Results 
 
Sustained Activation of the MEK/ERK Signaling Pathway Induces Endogenous 
DUSP4 mRNA and Protein in 3T3-L1 Adipocytes. Early evidence has demonstrated that 
DUSP4 can be upregulated in response to growth factors, inflammatory stress, 
oncogenes and UV radiation [24, 33-36]. Many of these stimuli are also known to 
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activate MAPK signaling pathways. Therefore, we investigated the effects of several 
MAPK agonists, TNF-, H2O2, UV irradiation and PMA on DUSP4 expression. Density-
arrested 3T3-L1 adipocytes were first stimulated and harvested over time and then 
immunoblotted with phospho-specific antibodies to identify MAPKs exclusively when 
being dually phosphorylated on the T-x-Y motif of the activation loop. As illustrated in 
Figure 2.1A, compared to 0h, treatment with either TNF- or H2O2 caused a rapid and 
transient induction of p-ERK, p-p38 and p-JNK that was gone by 1 hr. However, DUSP4 
expression was not detectable under either conditions as compared to the positive 
control sample for DUSP4. As shown in Figure 2.1B, UV exposure led to strong induction 
of p-p38 and p-JNK with sustained activity over 4 hrs while only minimal p-ERK induction 
was observed when compared to 0 hr, no treatment sample. Expression of DUSP4 was 
not detectable under this condition. PMA stimulation resulted in robust and sustained 
MEK/ERK activation up to 8 hrs while no induction of p38 or JNK was observed (Figure 
2.1C). The accumulation of DUSP4 protein was observed at 2 hrs post-PMA and 
remained upregulated up to 8 hrs. Interestingly, the level of DUSP4 mRNA peaked at 2 
hrs post PMA treatment, but decreased significantly by 4 hrs and remained low 
throughout the remainder of the experimental period (Figure 2.1D). To confirm that the 
induction of DUSP4 is dependent on the MEK/ERK signaling pathway, we pre-treated 
cells with MEK inhibitor U0126 for 15 min before addition of PMA (Figure 2.2A). 
Although a sustained MEK-independent p-ERK induction was observed, the magnitude 
was weaker as compared to control cells. DUSP4 protein expression was greatly 
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suppressed under this condition. To explore p-ERK magnitude versus duration, we 
treated cells with PMA for 1 hr before blocking ERK activation with U0126 (Figure 2.2B). 
We found that even though we initially induced the magnitude of p-ERK level to the 
same extent as control cells, shortened duration of ERK activity abolished DUSP4 
induction. Collectively, these data suggest that endogenous DUSP4 induction requires 
strong and sustained ERK activation in adipocytes. 
The MEK/ERK Signaling Pathway Regulates Endogenous DUSP4 Protein 
Stabilization. Data presented above demonstrate that endogenous DUSP4 is induced via 
the MEK/ERK signaling pathway. While DUSP4 mRNA only peaked at 2 hrs post-PMA, its 
protein remained abundant up to 8 hrs suggesting post-translational stabilization of 
DUSP4 protein may be involved. It has been reported that ERK activation affects protein 
stability of several DUSPs, including DUSP4, in other cell types [22, 24, 37]. Therefore, 
we speculated that endogenous DUSP4 protein can be stabilized by ERK activation in 
adipocytes. To test this hypothesis, DUSP4 was maximally induced with 2 hrs PMA 
pretreatment before stimulation with the protein synthesis inhibitor cycloheximide 
(CHX) to prevent additional protein synthesis. As illustrated in Figure 2.3A, although 
DUSP4 protein levels decreased upon CHX treatment, the remaining DUSP4 proteins 
were very stable as long as the levels of phospho-ERK remained elevated (18 hrs post-
CHX), indicating a long protein half-life of this phosphatase under the condition of 
sustained ERK activation. However, when cells were concomitantly treated with CHX 
and U0126 in combination, ERK activation was significantly suppressed, and DUSP4 
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protein stability decreased dramatically, yielding an estimated half-life of 1.5 hrs (Figure 
2.3B). These results suggest that DUSP4 protein stability depends on MEK/ERK 
activation. 
Proteasomal Activity is Involved in the Degradation of Endogenous DUSP4 
Protein. Previous studies have shown that proteasomal activity is involved in protein 
degradation of DUSPs, such as DUSP1, DUSP5 and DUSP6 [38-40]. To investigate the 
involvement of proteasomal activity towards DUSP4 protein degradation in adipocytes, 
DUSP4 was induced with PMA for 2 hrs before treating with U0126, CHX and 
proteasome inhibitor epoxomicin (EPOX). As illustrated in Figure 2.3C, when ERK 
activation was suppressed by U0126, addition of EPOX partially attenuated DUSP4 
protein degradation, extending its protein half-life to 4 hrs, as compared to cells in 
Figure 2.3D. Our results indicate that DUSP4 protein degradation is mediated by 
mechanisms involving proteasomal activity.     
Induction of DUSP4 Correlates with the Loss of ERK Phosphorylation in the 
Nucleus. It has been well established that phospho-ERK is a target of DUSP4 [33, 41, 42]. 
However, as shown in Figure 2.1C, the level of PMA-stimulated ERK phosphorylation did 
not decrease following DUSP4 induction, suggesting that persistent ERK phosphorylation 
may be exclusively localized to the cytoplasmic compartment. To test this hypothesis, 
subcellular localization of phospho-ERK and DUSP4 following PMA stimulation was 
analyzed by immunofluorescence microscopy with DAPI counterstaining used for 
defining nuclear compartment. As illustrated in Figure 2.4, phospho-ERK was detected in 
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the cytosol, but not the nucleus in quiescent, non-stimulated 3T3-L1 cells. DUSP4 was 
not detectable in either compartment under quiescent conditions. PMA stimulation for 
10 min induced rapid phospho-ERK accumulation in the nucleus prior to induction of 
DUSP4. With PMA stimulation for 2 hrs, nuclear phospho-ERK was significantly 
suppressed concomitant with nuclear accumulation of DUSP4 while cytosolic phospho-
ERK remained elevated. Additionally, phospho-ERK signal remained suppressed in the 
nucleus at 4 hrs post-PMA while DUSP4 continued to be expressed. Collectively, these 
data suggest that DUSP4 modulate ERK activity in a compartment-dependent manner 
that the phosphatase only controls ERK activation in the nucleus while not interfering 
with cytosolic ERK activation. 
Protein-protein Interactions Between DUSP4 and ERK. Data presented above 
demonstrate the loss of nuclear ERK signal is associated with the induction of DUSP4 in 
adipocytes. A number of studies have reported that while some DUSPs only 
dephosphorylate and release ERK, other DUSPs can anchor ERK protein within specific 
cellular compartments [42-44]. To further examine if DUSP4 can anchor and retain ERK 
protein in the nucleus, density-arrested 3T3-L1 cells were first treated with PMA and 
harvested at indicated times. Lysates were immunoprecipitated and immunoblotted for 
both ERK and DUSP4.  As illustrated in Figure 2.5, under basal conditions where there 
was no DUSP4, ERK did not co-immunoprecipitate with this phosphatase (lane 3). PMA 
stimulation for 4 hrs led to DUSP4 induction and DUSP4-ERK co-immunoprecipitation 
(lane 4).  Non-specific binding of lysate proteins to agarose coupling resin was ruled out 
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(lane 5). These data strongly suggest that DUSP4 can serve as an anchor protein for ERK, 
retaining the kinase in the nucleus. 
Discussion 
 
In this study, we demonstrated the regulation of endogenous DUSP4 by MAPKs 
activation in 3T3-L1 adipocytes. First, we report that DUSP4 induction required strong 
and sustained ERK activation. Blockade of ERK activity completely abolished DUSP4 
expression while JNK or p38 activation did not play a role in DUSP4 upregulation. 
Second, we show that sustained ERK activation also promoted DUSP4 protein stability. 
Third, we demonstrate proteasome activity was involved in DUSP4 protein degradation. 
Fourth, we present nuclear phospho-ERK was absent following induction of DUSP4 in 
the nucleus. Finally, we reveal protein-protein interaction between DUSP4 and ERK. 
Taken together, data presented in this report demonstrate that endogenous DUSP4 is 
regulated via the MEK/ERK signaling pathway and DUSP4 regulates ERK activation in a 
compartment-dependent manner in 3T3-L1 adipocytes.  
It has been well established that obesity-mediated chronic inflammation in 
adipose tissue leads to the production of pro-inflammatory cytokines such as TNF-α and 
IL-6. These inflammatory molecules can interfere with insulin signaling pathway and 
cause other obesity-associated metabolic disorders by activating intracellular signaling 
pathways including the MAPKs [5-7]. Traditionally, upon receiving appropriate 
extracellular signals, the MAPK signaling pathways mediate normal biological responses 
[9, 10]. However, aberrant MAPK activation by obesity-mediated inflammatory stress 
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has been shown to cause antagonist effects [3, 7, 45].  As MAPK signaling cascades are 
often depicted as simple and linear signaling transduction networks, a growing number 
of studies have demonstrated that differences in the duration, magnitude and 
subcellular localization of MAPK activities all contribute to specific and diverse cellular 
outcomes [46, 47]. Investigations in the past extensively focused on upstream activation 
of MAPK signaling. Accumulating evidence now suggests that MAPK deactivation by 
phosphatases also play a pivotal role in regulating signal specificity [15, 18]. The MAPK-
specific DUSPs are plausible candidates that have been shown to modulate MAPK 
dephosphorylation and subsequent cellular outcomes in various cell types [14-16, 48, 
49].  Studies have further demonstrated that, besides dephosphorylating MAPKs, 
several DUSPs were able to anchor their substrates in subcellular compartments adding 
to their versatility as MAPK regulators [19, 42, 50]. 
Although DUSP4 was one of the first DUSPs to be identified, information 
delineating its regulation and function in adipocytes has not been described. Previous 
studies have shown that DUSP4 can be induced by several extracellular signals that are 
also known to activate MAPKs, but the precise mechanism and involvement of MAPK 
activity in DUSP4 induction remains unclear. Data presented in this investigation 
demonstrate that PMA-mediated strong and sustained ERK activation led to significant 
induction of endogenous DUSP4 mRNA and protein. Blockade of ERK activation with 
U0126 completely abolished DUSP4 induction. In contrast, TNF- and H2O2-mediated 
transient ERK activation could not induce DUSP4. In addition, regardless of the signal 
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duration and magnitude, JNK or p38 activation did not contribute to DUSP4 
upregulation. Consistent with our observation, Cagnol and colleague also reported 
sustained oncogenic ERK activation promotes DUSP4 expression [22].  Taken together, 
our data demonstrate that the upregulation of DUSP4 is solely dependent on MEK/ERK 
signaling. 
Evidence from early studies indicates that ERK activation plays an important role 
in post-translational modification of DUSPs protein. For instance, DUSP1, DUSP5 and 
DUSP16 were reported to be stabilized by ERK phosphorylation [24, 39, 51], while 
DUSP6, on the other hand, is destabilized when phosphorylated by ERK [38]. These 
studies also suggest that DUSPs protein degradation is associated with proteasomal 
activity. Our findings demonstrated that without ERK activation, the protein half-life for 
endogenous DUSP4 was approximately 1.5 hrs. In contrast, DUSP4 protein half-life was 
significantly increased beyond 18 hrs with sustained ERK activation. In addition, under 
the condition of ERK suppression, inhibition of proteasomal activity by EPOX could 
extend DUSP4 protein half-life from 1.5 hrs to 3 hrs. Similarly, others have also shown 
that DUSP4 protein only yielded a short half-life of 7.5 min when ERK activity was 
suppressed, while its protein half-life was markedly extended to 1.5 hrs with sustained 
ERK activation in other cells [22]. Peng et al. also reported blockade of ERK 
phosphorylation promotes proteasome degradation of DUSP4 protein [37]. Collectively, 
our findings suggest that DUSP4 protein stability requires ERK phosphorylation in 
adipocytes and its protein degradation is partially mediated by proteasomal activity. 
 
59 
 
Growing evidence now clearly suggests that the magnitude, duration and 
localization of ERK signaling modulate diverse cellular outcomes [13, 47, 52-54].  Thus, 
ERK activity needs to be precisely controlled both spatially and temporally to prevent 
adverse effects due to aberrant MEK/ERK pathway activation. Data presented above 
demonstrate DUSP4 is induced in a MEK/ERK-dependent manner by sustained ERK 
activation and DUSP4, canonically functions in a negative feedback manner to 
dephosphorylate and inactivate ERK signaling [22, 25, 42]. However, we observed that 
PMA-induced ERK phosphorylation in whole cell lysates did not decrease following the 
induction of DUSP4 as visualized by immunoblotting. This led us to hypothesize that 
DUSP4 regulates ERK activity in the nucleus and that sustained ERK phosphorylation 
following DUSP4 induction is exclusively localized to the cytosolic compartment. Our 
observations supported the hypothesis by showing that nuclear ERK inactivation 
occurred concomitantly with nuclear induction of DUSP4. Furthermore, we have shown 
protein-protein interactions between ERK and DUSP4 by Co-IP. However, this DUSP4-
ERK interaction was only observed when we first immunoprecipitated DUSP4 protein 
and then immunoblotted for ERK. We were unable to detect protein-protein 
interactions when immunoprecipitated ERK and immunoblotted for DUSP4. One 
explanation would be that DUSP4 is exclusively localized to the nuclear compartment, as 
we immunoprecipitated sufficient amount of this phosphatase, a relatively strong 
DUSP4-ERK interaction signal could be detected by western blot. In contrast, ERK 
proteins are localized in both compartments of a cell and the ERK antibody recognizes 
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both activated and inactivated forms of ERK. Therefore, when we immunoprecipitated 
ERK proteins that comes from both cytosolic and nuclear compartments, those ERK 
proteins that attached to DUSP4 might be limited. As a result, the DUSP4-ERK 
association could be too weak to be detected. Collectively, these data support the 
hypothesis that DUSP4 regulate ERK phosphorylation in a compartment-dependent 
manner and it also serves as an anchor protein to retain ERK in the nucleus. It further 
suggests that sustained nuclear ERK activation could mediate adverse effects in 
quiescent cells. Therefore, specific nuclear regulator is expressed to modulate ERK signal 
at the appropriate time. Based on these preliminary findings, we developed the 
following working model (Fig.2.6), where sustained activation of ERK leads to its 
translocation from the cytosol to the nucleus that further induces nuclear DUSP4 
expression, and DUSP4 subsequently dephosphorylates and retains ERK in the nucleus 
from reactivation (Fig.2.6A). Meanwhile, ERK phosphorylation stabilizes DUSP4 from 
proteasome-mediated protein degradation (Fig.2.6B). 
In summary, this study provides the first evidence regarding regulatory 
mechanisms of endogenous DUSP4 by MAPK activation in adipocytes. Data presented 
here demonstrate that induction of endogenous DUSP4 requires strong and sustained 
ERK activation. We also report that ERK activity controls DUSP4 protein stability with the 
observation that, while loss of ERK signal led to rapid DUSP4 protein degradation, 
sustained ERK activation could maintain protein levels of DUSP4 during our 
experimental period. In addition, inhibition of proteasomal activity partially rescued the 
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loss of DUSP4 protein under the condition of ERK inactivation.  Our data further show 
that nuclear ERK phosphorylation was suppressed following induction of DUSP4 while 
cytosolic ERK remained activated, and DUSP4 co-immunoprecipitated with ERK, 
underlining the importance of negative feedback mechanisms by DUSP4 in 
spatiotemporal regulation of ERK activity in the nucleus. These data collectively suggest 
that ERK plays an important role in regulation of DUSP4 and DUSP4, in turn, provides a 
negative feedback control of nuclear ERK activation in 3T3-L1 cells. 
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Figure 2.1. DUSP4 Induction in Response to Agonist-specific MAPKs Activation. 
Preadipocytes were stimulated with A) 300 µM H2O2 or 100 pM TNF-α, B) 100J/m2 UV 
radiation and C) 300 nM PMA. Cell lysates were collected at indicated times and protein 
expression of bisphosphorylated MEK, ERK, p38 and JNK as well as DUSP4 and α-
tubulin was analyzed via immunoblotting. PC: positive control for DUSP4. D) Total RNA 
was harvested from PMA-stimulated preadipocytes and mRNA expression of DUSP4 
measured using qRT-PCR. Data were normalized to 18S rRNA and changes in gene 
expression measured as fold differences relative to untreated preadipocytes (0h).  
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Figure 2.2. Magnitude and Duration of ERK Activity Determines DUSP4 Protein 
Expression. A) Preadipocytes were stimulated with 300nM PMA in the absence or 
presence of 20 µM U0126 prior to immunoblot analysis of bisphosphorylated ERK as 
well as DUSP4 and α-tubulin. B) PAs were stimulated with PMA for 1 hr before addition 
of U0126 or vehicle. Cell lysates were collected at indicated times and protein 
expression of bisphosphorylated ERK along with dusp4 and α-tubulin analyzed via 
immunoblotting. 
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Figure 2.3. ERK Activity Determines DUSP4 Protein Stability and Proteasomal 
Activity is Involved in DUSP4 Protein Degradation. Preadipocytes were pretreated 
with PMA for 2h before addition of A) 5µM cycloheximide (CHX), B) U0126+CHX, or 
C) U0126+CHX+ 5µM Epoxomicin (Epox). Lysates were collected at indicated times 
and protein expression of bisphosphorylated ERK and DUSP4 analyzed via 
immunoblotting. NT: no treatment. D) Remaining DUSP4 protein abundance was 
determined by densitometry and plotted as a percent of control for half-life 
determination.   
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Figure 2.4. Inhibition of ERK Phosphorylation following DUSP4 Expression in the 
Nucleus. Preadipocytes were grown on a 4-well chamber slide and stimulated with 
PMA. Subcellular compartmentalization of bisphosphorylated ERK (green) along with 
DUSP4 (red) was assessed at indicated times by immunofluorescence. DAPI (4',6-
diamidino-2-phenylindole) staining (blue) was performed to reveal location of nucleus. 
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Figure 2.5. Protein-protein Interactions Between DUSP4 and ERK. Cells 
lysates were harvested from density-arrested 3T3-L1 PA at 0 hr and 4 hrs post-
PMA (300nM), immunoprecipitated for ERK (lane 1 and 2) and DUSP4 (lane 3 
and 4), immunoblotted for DUSP4 and ERK. Lane 5: control, resin with no 
antibody attached. Lane 6 and 7: whole cell lysates. 
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Figure 2.6. Proposed Working Model for Regulation and Function of 
DUSP4 in Response to Sustained ERK Activation in Adipocytes. 
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CHAPTER III 
 
ROLE FOR DUAL-SPECIFICITY PHOSPHATASE 4 IN ADIPOCYTE DIFFERENTIATION 
 
 
Abstract 
 
Chronic adipose tissue (AT) inflammation is central to pathogenic mechanisms 
linking obesity and insulin resistance (IR). There is strong evidence demonstrating that 
mitogen-activated protein kinases (MAPKs) are important signaling mediators linking 
inflammation to obesity-induced IR. While numerous studies have examined upstream 
signaling kinases that are critical for MAPK activation, few have examined the biological 
outcomes of MAPK deactivation by MAPK-specific, dual specificity phosphatases 
(DUSPs). To address the latter, we determined the expression profile of the 10 known 
DUSP family members in insulin-responsive tissues of genetic-induced obese (GIO) and 
diet-induced obese (DIO) mice that are known to have elevated degrees of 
inflammation. We demonstrated that DUSP4 and DUSP9 mRNAs were significantly and 
markedly (>10-fold) more abundant in lean AT isolated from C57BL/6J male mice 
relative to liver, skeletal muscle and heart. Examining sequential stages of GIO and DIO 
mice, we determined that DUSP9 was the only DUSP with elevated mRNA in obese 
versus lean AT. In contrast, DUSP4 mRNA inversely correlated with the degree of 
inflammation associated with both models of obesity. Using 3T3-L1 adipocytes, we 
further demonstrated biphasic induction of DUSP4 during adipocyte differentiation,
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with early phase induction of this phosphatase being ERK-dependent and late stage 
induction being ERK-independent and differentiation-specific. Moreover, DUSP4 was 
significantly and markedly suppressed by TNF-α in adipocytes. However, DUSP4 
antisense expression did not inhibit 3T3-L1 adipogenesis. Collectively, these results 
suggest that tissue-specific regulation of DUSP4 may contribute to obesity-mediated 
inflammation and IR. Furthermore, our findings establish a platform for future 
investigations towards the function of DUSP4 in obesity-associated inflammation. 
Introduction 
 
Obesity is one of the most prevalent nutrition-related physiological disorders 
that contributes to the development of a variety of chronic health problems such as 
cardiovascular diseases, dyslipidemia, hypertension, nonalcoholic fatty liver disease, 
insulin resistance (IR), type II diabetes (T2D) and certain cancers [1-4]. The increasing 
rate of obesity, and its concomitant health risks, makes it one of the greatest threats to 
global health [1, 5]. While adipose tissue (AT) has been historically considered as a 
reservoir for storing excess energy,  extensive research over the past few decades has 
shown that AT is a biologically active endocrine organ which plays an important role in 
regulating whole-body homeostasis [6, 7]. However, obesity could negatively impact AT 
function by alteration of major signaling pathways, leading to IR and other molecular 
dysfunctions [8-10]. A number of studies have shown that pro-inflammatory cytokines, 
such as monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6 and tumor 
necrosis factor-α (TNF-α), are increased with obesity [8, 9, 11-13]. These inflammatory 
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molecules trigger inflammatory responses by various mechanisms, one of which is 
through the activation of the mitogen activated protein kinases (MAPKs). 
It is well established that MAPKs play an important role in various cellular 
processes. Most of the functional studies of MAPK are focused on three major groups: 
extracellular signal-regulated kinases (ERKs), c-Jun amino-terminal kinases (JNKs) and 
p38 kinases. MAPK activation requires dual phosphorylation of threonine and tyrosine 
residues of the (T-X-Y) motif within the activation loop by specific upstream MAPK 
kinases [14, 15]. Activated MAPKs participate in the transcriptional activation of a 
number of genes that promote differential cellular outcomes such as proliferation, 
differentiation, inflammation and apoptosis [16]. Adipocyte hyperplasia (cell number 
increase) and hypertrophy (cell size increase) are crucial mechanisms for the 
development of obesity, and are dependent on adipocyte differentiation [7, 16-18]. 
Many research labs have extensively investigated the role of MAPKs in adipocyte 
development under normal and pathological states. Evidence has revealed that early, 
transient ERK activation is required for adipocyte differentiation while blocking ERK 
activity suppresses this process [17, 19, 20]. Similarly, p38 activation is required for 
adipocyte differentiation, while persistent activation can lead to the death of adipocytes 
[21-23]. Activation of JNK by free fatty acids has been shown to reduce glucose uptake 
by alteration of insulin receptor-mediated signal transduction, which leads to 
suppressed glucose transporter type 4 (GLUT4) translocation [24]. Peroxisome 
proliferator-activated receptor γ (PPARγ) is a nuclear transcription factor that is highly 
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expressed in AT and considered a master regulator of adipogenesis. Activation of PPARγ 
initiates transcription of genes that regulate lipid and glucose metabolism as well as 
suppressing inflammatory genes in adipocytes [24-26]. Studies have shown that 
phosphorylation of PPARγ by MAPKs suppresses its transcriptional activity, thereby 
leading to impaired adipogenesis and insulin sensitivity [27-29]. 
While upstream kinases have been extensively studied regarding MAPK 
activation in the past, growing evidence now strongly suggests protein phosphatases, 
including protein tyrosine phosphatases (PTPs), serine/threonine phosphatases (PPs) 
and dual-specificity phosphatases (DUSPs), as important regulators of MAPK activity [30, 
31]. While the first two groups only dephosphorylate single tyrosine or threonine 
residues, DUSPs dephosphorylate both residues [32]. Of the many identified DUSPs, a 
group of 10 DUSPs contains a common MAPK-binding (MKB) domain that specifically 
confers catalytic activity toward MAPKs [32-34]. These DUSPs are further divided into 
three subfamilies based on their sequence, substrate specificity and localization. Type I 
DUSPs includes DUSP1, DUSP2, DUSP4 and DUSP5, all of which are localized to the 
nuclear compartment and can be induced by mitogenic or stress signals. Type II DUSPs 
comprises DUSP6, DUSP7 and DUSP9, which are ERK-specific cytosolic DUSPs. The last 
group containing DUSP8, DUSP10 and DUSP16 are JNK/p38-specific phosphatases that 
are localized within both the cytosolic and nuclear compartment [30, 32]. 
In recent years, investigators have started to uncover roles of DUSPs in obesity-
induced IR and adipocyte dysfunction. For instance, DUSP1 is an immediate early gene 
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that is induced during adipocyte differentiation [35]. DUSP1 knockdown lead to 
prolonged activation of ERK and p38 without inhibiting adipocyte differentiation [35]. 
Mice lacking DUSP1 were protected against diet-induced obesity (DIO) [36]. DUSP9 is 
also induced during late stages of adipocyte differentiation [35]. Overexpression of 
DUSP9 in 3T3-L1 cells suppressed ERK and JNK activation, leading to improved insulin 
sensitivity and glucose tolerance against obesity-induced inflammatory stress [37]. In 
addition, studies have revealed that DUSP6 is involved in glucose and lipid metabolism 
and DUSP6-deficient mice are protected against DIO [38, 39].  
Considering DUSPs as controllers of MAPK signaling and the potential of DUSPs 
against obesity-induced chronic inflammation, we explored the role of DUSP4 in 
adipocyte differentiation. Initial screening of DUSP4 revealed that, among major 
biologically active insulin-responsive tissues, DUSP4 was expressed more abundantly in 
white AT relative to liver, skeletal muscle, and heart of lean mice. Expression of DUSP4 
was markedly suppressed in animal models of genetic and diet-induced obesity with 
elevated production of inflammatory markers. Using the murine 3T3-L1 cell line as a 
model of adipogenesis, we further demonstrated that DUSP4 was induced biphasically 
during adipocyte differentiation. While DUSP4 induction during early phase of adipocyte 
differentiation (4 hrs) required ERK signaling, the late phase DUSP4 induction (d4-d5) 
appeared to be ERK-independent and specific to differentiation, regardless of cell type. 
Additionally, DUSP4 knockdown was not sufficient to block adipogenesis. Collectively, 
our findings provide the first molecular evidence demonstrating the regulation of DUSP4 
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during adipocyte differentiation, highlighting a potential role for DUSP4 as a prospective 
target for obesity-associated metabolic dysfunctions.   
 
Materials and Methods 
 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
Trypsin-EDTA, and recombinant murine TNF-α were purchased from Invitrogen. Fetal 
bovine serum (FBS) was obtained from HyClone. The following antibodies were used for 
immunoblot analysis: phospho-MEK, phospho-ERK (Thr202/Tyr204), phospho-p38 
(Thr180/Tyr182), phospho-JNK (Thr183/Tyr185), and α-tubulin were purchased from 
Cell Signaling; DUSP4 was purchased from Santa Cruz Biotechnology. Pharmacological 
inhibitors of ERK (U0126), JNK (SP600125) and p38 (SB203580) were purchased from 
CalBiochem. Troglitazone was purchased from Cayman Chemical. Enhanced 
chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life Sciences. All 
TaqMan primer probes used in this study were purchased from Applied Biosystems. 
Mice and Experimental Diets. Animals used for this study include genetically 
obese male B6.V-Lepob/J (B6-ob/ob) mice and their lean littermates as well as C57BL/6J 
mice rendered obese by diet and their lean controls. All mice were housed and treated 
by the supplier (Jackson Laboratories, Bar Harbor, Maine) until shipment 1 wk prior to 
tissue harvest. B6-ob/ob mice and lean littermates were purchased for experimentation 
at 6 wks and 10 wks of age and given free access to a standard laboratory chow diet. 
C57BL/6J mice subjected to diet-induced obesity (DIO) were fed a high fat diet (HFD) 
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consisting of 60% kcal from fat (Research Diets Inc. D12492) from 6 wks of age. Lean 
C57BL/6J control mice were fed a control low fat diet (LFD) consisting of 10% kcal from 
fat (Research Diet Inc. D12450B) from 6 wks of age. Both diets contained 10% kcal from 
protein with the balance in caloric value provided by differences in carbohydrate 
content. Mice receiving both diets were given free access to food and shipped for 
experimentation at 18 wks and 24 wks of age. All animals were euthanized by CO2 gas 
asphyxiation and epididymal AT, liver, calf skeletal muscle, and ventricular heart tissue 
collected and processed for preparation of total RNA. Animal care and use was in 
compliance with the Institute of Laboratory Animal Research Guide for the Care and Use 
of Laboratory Animals and approved by the Institutional Animal Use and Care 
Committee. 
Cell Culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School. Cells were propagated in DMEM supplemented with 10% CS 
until reaching density-induced arrest, as previously described. Throughout the study, 
‘time 0’ refers to density arrested cells immediately before the addition of MDI to the 
culture medium. Experiments described herein were conducted in density-arrested 
preadipocytes. All experiments were repeated 2-3 times to validate results and ensure 
reliability. 
Immunoblotting. Cell monolayer were washed with phosphate-buffer saline  
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM NaCl, 
10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 
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1 mM EGTA. Phosphatase inhibitors (20 mM β-glycerophosphate, 10 mM sodium 
fluoride and 2 μM sodium orthovanadate) and protease inhibitors (0.3 μM aprotinin, 21 
μM leupetin, 1 μM pepstatin, 50 μM phenanthroline, 0.5 μM phenylmethylsulfonyl 
fluoride) were added to lysis buffer immediately prior to cell harvest. Cell lysates were 
sonicated and centrifuged (15,000g, 10 min, 4°C), and the supernatant transferred to a 
fresh tube. Protein content was determined by bicinchoninic acid (BCA) procedures 
according to manufacturer’s (Pierce, Rockford, IL) instructions. Equal amounts of whole 
lysate protein were separated by SDS-PAGE electrophoresis. Cell lysates were mixed 
with loading buffer containing 0.25M Tris (pH6.8), 4% SDS, 10% glycerol, 0.01% 
bromophenol blue, and 10% dithiothreitol, then heated at 80°C for 5 min prior to 
electrophoresis. Proteins were resolved on SDS-polyacylamide gel electrophoresis 
(PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore corp., 
Billerica, MA). After transfer, membranes were blocked with 4% milk and probed with 
indicated primary antibodies overnight at 4°C. Membranes were subsequently probed 
with horseradish peroxidase conjugated secondary antibodies for 2 hrs at room 
temperature. Membranes were immersed in ECL and data visualized by 
autoradiography using CL-XPosure film (Pierce).  
Real-Time RT-PCR. Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to 
manufacturer protocol. Total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer. Total RNA was reverse-transcribed to cDNA in a 10 μl reaction 
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volume using a high capacity cDNA reverse transcription kit (Applied Biosystems). The 
reverse transcription (RT) master mix containing RT buffer, deoxyribonucleotide 
triphosphate (dNTP) mix, RT random primers, RNase inhibitor (1.0 U/μl), and MultiScribe 
RT was added to 1 μg RNA and RNase-free water. Reverse transcription reaction 
conditions followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, 
followed by 4°C indefinitely/ RT complete) and utilized the Gene Amp PCR System 9700 
thermal cycler (Applied Biosystems) for cDNA synthesis.  
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing /extension at 60°C for 30 sec. 
All data were analyzed with the ABI 7500 real time PCR system. All TaqMan primer 
probes used in this study were also purchased from ABI. Data were recorded and 
analyzed with ABI Sequence Detector Software and graphs visualized with SigmaPlot 
software. All data were presented as mean ± standard error of the mean (SEM) and 
representative of duplicate determinations. Data were normalized to 18S and measured 
as relative differences using the 2-ΔΔCT method as previously described [40, 41]. 
Statistical analyses were conducted using SPSS v18. Differences in gene 
expression between lean and obese animals were determined via student’s t-test where 
a p-value of <0.05 was considered significant. Data regarding mRNA tissue distribution 
were analyzed using analysis of variance (ANOVA), with Tukey's posthoc analysis used 
when the p-value for the respective parameter was statistically significant (p < 0.05). 
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RNA Interference. Lentiviruses were generated using the 2nd generation 
Lentiviral packaging plasmid (psPAX2) and envelope plasmid (pMD2.G) purchased from 
Addgene. Polyethylenimine (Polysciences) was used to transfect HEK L293 cells either 
with vectors containing DUSP4-specific shRNA (TRCN0000054351, Signa-Aldrich) or a 
non-targeted scramble shRNA. Stable knockdown 3T3-L1 cell line was produced by 
lentiviral transduction with either DUSP4 targeting shRNA or scrambled shRNA in the 
presence of 10µg/mL polybrene and selected in 10% CS medium containing 5µg/mL 
puromycin (Invitrogen) for 10 days. The selected clones were subsequently maintained 
in fresh puromycin-containing medium, analyzed, and used for experiments as 
described above. 
 
Results 
 
Expression of DUSP4 in Insulin-responsive Tissues of Lean C57BL/6J Male Mice.  
A number of studies have revealed that obesity-induced chronic inflammation leads to 
aberrant MAPKs activation which further contributes to the development of IR [28, 42-
44]. Correspondingly, accumulating evidence has also shown that select DUSPs play a 
role in modulating MAPK activity and insulin signaling under inflammatory stress [37, 39, 
45, 46]. Thus, we initially sought to examine relative mRNA expression of all 10 MAPK-
specific DUSPs in major types of insulin-responsive tissues, such as epididymal white AT 
(WAT), liver, skeletal muscle and heart, from C57BL/6J wildtype mice using qRT-PCR. 
DUSPs mRNA abundance were normalized to 18S ribosomal RNA and expressed as fold-
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differences relative to WAT. We report that, within the nuclear DUSP group, only DUSP4 
mRNA was ~14-fold more abundant in WAT compared to liver, skeletal muscle and heart 
(Fig.3.1A). Similar tissue distribution was noted for cytosolic DUSP9 where relative 
mRNA was markedly more abundant (~50 fold) in WAT relative to all the other three 
tissue types (Fig.3.1B). The remaining DUSPs exhibited divergent tissue distribution 
(data not shown). Collectively, these data suggest the potential of tissue-specific 
regulation and function of DUSP4 and DUSP9.  
Regulation of DUSP4 and DUSP9 in WAT during the Progressive Dvelopment of 
Genetic and Diet-induced Obesity. Data presented above demonstrated that both 
DUSP4 and DUSP9 were significantly more abundant in AT relative to other insulin-
responsive tissues. Since accumulating evidence now clearly suggests that AT is the 
predominant site for the development of obesity-induced metabolic dysfunction, we 
next examined if expression of DUSP4 and DUSP9 were impacted under pathological 
progression of obesity using two distinct stages and models of obesity (genetic vs diet-
induced obesity). For development of genetic-induced obesity (GIO), B6-ob/ob mice 
exhibit hyperplasia with ensuing obesity notable at 1 month of age and transient 
glucose intolerance that begins at ~6 wks of age and subsides between 12-16 wks of 
age, according to the supplier. Thus, to compare the progression of obesity, 6 wk and 10 
wk old ob/ob mice and wildtype littermates, representing sequential stages (early vs. 
mid-stage) of obesity with developing obesity-related metabolic disorders, were chosen 
for this study. For development of diet-induced obesity (DIO), C57BL/6J male mice were 
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fed a high fat diet (HFD; 60% kcal from fat) starting at 6 wks of age by the supplier. 
Control littermates were fed a control diet (CD) containing 10% kcal from fat. Both diets 
contained 10% kcal from protein with the balance in caloric value provided by 
differences in carbohydrate content. Studies were conducted at 18 wks and 24 wks of 
age, representing 12 wks and 18 wks of dietary intervention, respectively. Progression of 
obesity development in both models were arbitrarily designated as stage I and stage II. 
Using these two models, we determined relative mRNA abundance for DUSP4 and 
DUSP9 as well as other well-known inflammatory markers of obesity (i.e., MCP-1, TNF-α, 
and IL-6) in WAT where fold-differences were determined between obese and lean 
values at different sequential stages of obesity. Adipsin was also assessed to confirm the 
onset of obesity at each stage as others have reported a significant suppression of this 
adipocyte-specific gene in WAT isolated from obese animals compared to their lean 
littermates [47, 48]. 
As illustrated in Fig.3.2, adipsin was markedly suppressed as ob/ob mice 
transitioned from stage I (40-fold reduction) to stage II (80-fold reduction) obesity.  
Similarly, adipsin expression progressively decreased (7-fold vs. 25-fold) in both stages 
of DIO mice. MCP-1 has been shown to promote macrophage infiltration into AT during 
onset of obesity [13, 49-51]. Consistent with others, we observed MCP-1 induction 
which was greater than 7-fold at both stages of development and in both models of 
obesity. Relative mRNA abundance of IL-6 and TNF-α was only significantly induced in 
stage II ob/ob mice fed a standard chow. Conversely, both cytokines were elevated in 
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DIO mice fed 12-wk HFD (stage I) with progressive increases in TNF-α (3-fold vs. 6-fold) 
correlating with the progression of obesity (18-wk HFD, stage II). DUSP4 expression 
increased only in stage I genetic (ob/ob) mice while no significant changes were 
observed for IL-6 and TNF-α. Induction of DUSP4 was not detected in late stage ob/ob 
mice with elevated production of IL-6 and TNF-α. Regarding DIO, DUSP4 mRNA 
expression showed no marked difference after 12 wks of HFD (stage I) and was even 
suppressed after 18 wks of HFD (stage II) while TNF-α expression progressively 
increased. Interestingly, in both animal models of obesity, DUSP9 mRNA abundance 
increased during each stage of development. In addition, DUSP9 gene expression also 
progressively increased as mice transitioned from stage I to stage II obesity in both 
models. Collectively, these data demonstrated gene expression of DUSP4 and DUSP9 
was divergently regulated in WAT based on the progressive stage of obesity 
development, the progressive inflammatory environment as well as the model of 
obesity. 
Regulation of DUSP4 during Early and Late Stages of Adipocyte Differentiation. 
The progression of obesity involves adipocyte hyperplasia and hypertrophy and 
adipocytes are the most predominant cell type in AT [7, 18]. While others have already 
studied the role for DUSP9 in adipocytes [37, 52], information regarding regulation and 
function of DUSP4 in adipocytes is still limited. This led us to investigate the regulation 
of DUSP4 during the course of adipocyte differentiation. Density-arrested preadipocytes 
were stimulated with hormonal differentiation cocktail (i.e., MDI). Total RNA and whole 
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cell lysates were collected over early (0-24hr) and late (d0-d9) stages of differentiation. 
DUSP4 mRNA and protein expression as well as MAPK phosphorylation and PPARγ 
expression were examined via qRT-PCR and immunoblot analysis, respectively. As 
illustrated in Fig.3.3, during the early stage of differentiation, addition of MDI led to 
immediate, robust ERK phosphorylation that peaked within 10 mins and decayed to 
basal levels within 6 hrs of stimulation (Fig.3.3A). DUSP4 mRNA and protein levels 
kinetically and transiently increased (4-fold) at 4 hrs post-MDI in a feedback manner 
where expression of this phosphatase was inversely proportional to ERK 
phosphorylation (Fig.3.3A and B). Expression of this phosphatase returned to baseline 
value by 24 hrs post-MDI. More surprisingly, we observed a more sustained induction of 
DUSP4 starting at 4d, correlating with the expression of adipogenic marker PPAR, and 
remaining above baseline throughout the course of adipocyte differentiation (Fig.3.3C 
and D).  
Using MAPK inhibitors that selectively inhibit ERK, JNK or p38 activation, we 
demonstrated that induction of DUSP4 during the early phase of differentiation was 
mediated via MEK/ERK signaling as only ERK inhibitor U0126 suppressed DUSP4 
expression (Fig.3.4A). In contrast, induction of DUSP4 during the late stages of adipocyte 
differentiation was not suppressed by any MAPK inhibitor (Fig.3.4A) as phosphorylation 
state for all three MAPKs remained unchanged or even decreased throughout this period 
(Fig.3.4B). To determine the regulation of DUSP4 under inflammatory stress, PAs and 
ADs were stimulated in parallel with 100 pM TNF-α and relative mRNA abundance 
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assessed by qRT-PCR over time. As illustrated in Fig.3.5, mRNA levels for DUSP4 were 
markedly suppressed in both cell types where the degree of suppression was sustained 
throughout the course of the experiment.  
As the ERK-independent DUSP4 induction occurred concomitantly with the 
expression of adipogenic marker PPAR, we next stimulated PAs with MDI in the 
presence or absence of troglitazone (TROG) to determine if DUSP4 is a downstream 
target of PPAR. TROG is a potent agonist that increases PPAR transcriptional activity 
while also induces its protein degradation [53, 54]. As illustrated in Fig.3.6A, DUSP4 
protein expression did not increase with addition of TROG during adipocyte 
differentiation. We further sought to investigate if the ERK-independent DUSP4 
induction was specific to 3T3-L1 cells or to the process of differentiation. First, density-
arrested non-adipogenic NIH 3T3 cells [55] were stimulated with MDI and cell lysates 
harvested over time and immunoblotted for DUSP4 and PPAR. As illustrated in Fig.3.6B, 
MDI did not induce NIH 3T3 cell differentiation and expression of PPAR and DUSP4 was 
not detected. Second, adipogenic 3T3-F442A cells [56] were induced to differentiation 
with insulin over time in the presence or absence of TROG and immunoblotted for 
DUSP4 and PPAR. Consistent with the MDI experiment above, induction of DUSP4 and 
PPAR was observed during F442A cells differentiation and DUSP4 protein expression did 
not further increase with the addition of TROG (Fig.3.6C). Taken together, these data 
demonstrate that mid-stage induction of DUSP4 in dependent on differentiation as 
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opposed to chemical inducers and suggest a potential role for DUSP4 during latter stages 
of adipogenesis.    
DUSP4 Knockdown does not Inhibit Adipocyte Differentiation. Data presented 
above demonstrate that DUSP4 induction during late stages of adipocyte differentiation 
is MAPK-independent and specific to differentiation. To examine a role for DUSP4 during 
differentiation, we first established a stable DUSP4 knockdown 3T3-L1 cell line using 
short hairpin RNA lentiviral particle and appropriate antibiotic selection before inducing 
to differentiate. Total RNA was collected over time during differentiation and DUSP4 
mRNA expression was examined via qRT-PCR. Phase contrast microscopy was 
performed to assess changes in cell morphology and lipid accumulation at early (d0), 
mid (d4) and late (d8) stages of differentiation. As shown in Fig.3.7A, compared to L1 
control cells, DUSP4 knockdown cells exhibited 75% less DUSP4 mRNA at the beginning 
of differentiation. ERK-independent DUSP4 induction during late stages of 
differentiation was also significantly suppressed in knockdown cells. No discernible 
differences of morphology or lipid accumulation were observed between these two 
groups of cells during differentiation (Fig.3.7B). These data suggest a role for DUSP4 in 
adipocytes independent from adipocyte differentiation.  
Discussion 
 
In this study, we present the first empirical evidence regarding the regulation of 
DUSP4 in major insulin responsive tissues under conditions of obesity, as well as roles 
for DUSP4 in 3T3-L1 adipocytes. First, we demonstrate that DUSP4 was significantly 
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more abundant in WAT of lean animals relative to liver, skeletal muscle and heart. 
Second, we show that DUSP4 in WAT was suppressed with the degree of inflammation 
in both genetic and diet-induced models of obesity. Third, we reveal biphasic induction 
of DUSP4 during early and late stages of adipocyte differentiation as well as suppression 
of DUSP4 by inflammatory cytokine TNF-α in both PAs and ADs. Fourth, we show that 
while early phase DUSP4 induction was in response to ERK activation, induction of this 
phosphatase during mid-to-late stages of adipocyte differentiation appeared to be ERK-
independent and specific to differentiation regardless of cell type. Finally, we 
demonstrate that DUSP4 specific knockdown was not sufficient to block adipocyte 
differentiation. Collectively, these data provide novel insight regarding DUSP4 in WAT 
under conditions of obesity as well as during adipocyte differentiation, potentially 
establishing new therapeutic targets against inflammatory stress and metabolic 
disorders that are associated with obesity. 
It is well documented that obesity-associated chronic inflammation is crucial for 
the development of IR and other systemic metabolic diseases [4, 5, 7]. Accumulating 
evidence also shows that members of MAPK-specific DUSPs exhibit restricted expression 
in different tissue types [30, 31], allowing individual phosphatases to modulate MAPK-
dependent biological processes involved in insulin signaling [37, 39, 57]. Therefore, we 
first evaluated expression patterns of these DUSPs in four major metabolically active 
insulin-responsive tissues under normal physiological condition. Data presented here 
demonstrate that expression of DUSP4 and DUSP9 was significantly more abundant in 
 
90 
 
WAT relative to liver, skeletal muscle and heart, highlighting the potential for individual 
DUSPs in tissue-specific regulation of MAPK events that contribute to obesity-mediated 
IR and other metabolic inflammatory diseases.  
Previous studies have clearly demonstrated that WAT is the predominant site for 
the production and secretion of inflammatory molecules that cause IR and metabolic 
dysfunction [7, 10]. Moreover, WAT inflammation develops gradually over the course of 
obesity, where infiltration of macrophages as well as production of inflammatory 
cytokine and chemokine increases with the development of obesity [6-9, 13]. Data 
presented above demonstrate that, in the GIO model, MCP-1 was the only inflammatory 
marker increased in WAT of 6 wk old B6-ob/ob mice (stage I), while MCP-1, IL-6 and 
TNF-α were all elevated in WAT of 10 wk old B6-ob/ob mice (stage II). However, in the 
DIO model, all three inflammatory markers were already elevated in WAT of mice fed a 
12wk HFD (stage I). In addition, TNF-α expression continued to increase in mice fed HFD 
for 18 wks (stage II). In contrast, the expression of adipsin in WAT significantly 
decreased at these two sequential stages and in both models of obesity, indicating the 
development of obesity. Collectively, these data demonstrate that the degree of WAT 
inflammation is positively correlated with the development of obesity. 
Data presented here also revealed that DUSP4 and DUSP9 were divergently 
regulated in WAT based on the stage and model of obesity as well as the degree of 
inflammation associated with obesity. We observed induction of DUSP4 only in WAT of 
stage I GIO mice where there was no elevated gene expression of TNF-α. DUSP4 was 
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suppressed at the sequential stage of GIO mice as well as in both stages of DIO mice 
where TNF-α was markedly induced. In contrast, we demonstrate that DUSP9 was 
significantly induced in WAT of GIO and DIO mice at both stages, paralleling the elevated 
inflammatory cytokine gene expression. Consistent with our findings, other studies also 
reported that DUSP9 was elevated in WAT of mice under conditions of obesity [37, 58].  
Collectively, these data suggest that progression of obesity-induced inflammation may 
be responsible for the divergent regulation of DUSP4 and DUSP9 in WAT. 
It is widely accepted that WAT is comprised of many different cell types with ADs 
being the most predominant cells. While studies in the past extensively investigated the 
effect of MAPK activation in adipogenesis, recent reports have begun to elucidate roles 
of DUSPs in adipogenesis with growing evidence pointing to DUSPs as key modulators 
controlling cell signaling and biological outcomes. For instance, earlier evidence showed 
that genetic ablation of DUSP1 inhibits adipocyte differentiation [59]. However, 
contradictory findings from a more recent study demonstrated that genetic loss of 
DUSP1 leads to sustained ERK and p38 activation during early phase of adipocyte 
differentiation, but with no effect on adipogenesis[35]. Moreover, DUSP9 gain-of-
function studies showed that overexpression of this phosphatase blocks adipogenesis 
and protects cells against inflammatory stress-induced IR [37, 52]. As the role of DUSP4 
in adipocytes remains largely unknown, data presented in our report demonstrate 
biphasic induction of DUSP4 during adipocyte differentiation. The early phase DUSP4 
induction is mediated via the MEK/ERK signaling as blocking ERK activity by U0126 
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significantly suppressed DUSP4 expression. Interestingly, we find a second peak of 
DUSP4 induction during mid-to-late stages of adipocyte differentiation occurring 
concomitantly with the induction of PPARγ. This late phase induction is independent of 
MAPK activity as phosphorylation of all three MAPKs remained at basal levels 
comparable to untreated PAs (d0) throughout the entire experimental period. We also 
observed TNF-α-mediated marked suppression of DUSP4 in PAs and ADs, which is 
consistent with the finding from our in vivo study that inhibition of DUSP4 is 
accompanied by the progressive increase of inflammatory cytokine TNF-α during the 
development of obesity. Upon further examination, we revealed that DUSP4 is not 
downstream of PPARγ, suggesting a potential role for DUSP4 in protecting PPARγ 
against aberrant MAPK activation as phosphorylation of PPARγ by MAPKs has been 
shown to suppress transcriptional activity during adipogenesis [27-29]. In addition, by 
using NIH-3T3 and NIH-F442A cells, we report that the late phase induction of DUSP4 is 
not cell-type, but differentiation-specific. By establishing DUSP4 knockout 3T3-L1 cell 
line, we further demonstrate that suppression of DUSP4 is not sufficient to block 
adipocyte differentiation. Taken together, these data demonstrate unique regulation of 
DUSP4 during adipocyte differentiation while its exact role regarding MAPK activity and 
adipogenesis remain unresolved. 
In summary, this study provides the first comprehensive analysis showing that 
members of the MAPK-specific DUSP family are divergently regulated in a tissue-specific 
manner under conditions of obesity. Data outlined here and elsewhere [37, 52] 
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demonstrated that expression of DUSP9 in WAT is upregulated with the developmental 
stage of obesity. DUSP4, on the other hand, induced during the early-stages of obesity 
when there are no elevated levels of TNF-α, and significantly suppressed at the 
sequential stage of obesity characterized by the increased inflammation associated with 
obesity. Data presented here further demonstrate the biphasic induction of DUSP4 
during adipocyte differentiation. While the early phase DUSP4 induction is ERK-
dependent, the late phase induction is differentiation-specific, regardless of cell type. 
Moreover, knockdown of DUSP4 alone did not block adipogenesis, suggesting that 
DUSP4 may function independently from adipogenesis. Conclusions drawn from our 
data have led to the following working model (Fig.3.8). Obesity-mediated inflammation 
leads to PPARγ phosphorylation by aberrant MAPK activation, resulting in degradation 
of PPARγ and suppression of PPARγ transcriptional activity during adipogenesis 
(Fig.3.8A). DUSP4 negatively control MAPK activation, which could potentially protect 
PPARγ from being phosphorylated by MAPK so that PPARγ can maintain normal function 
during adipocyte differentiation (Fig.3.8B). As investigations on DUSP4 continue, 
elucidation into the mechanistic role of DUSP4 will shed new lights on the progression 
and regulation of AT inflammation and provide novel therapeutic targets for treatment 
of obesity-associated metabolic dysfunction and IR. 
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Figure 3.1. Tissue-specific Expression of DUSP4 and DUSP9. Epididymal white AT 
(WAT), liver, skeletal muscle (SK Muscle), and heart were harvested and total RNA 
prepared from C57BL/6J male mice. Gene expression of all ten DUSPs was analyzed 
via qRT-PCR. All data were normalized to 18S rRNA and tissues set relative to WAT. 
Statistical ANOVA was used to determine significant differences, p<0.05. Tukey's post-
hoc analysis was performed when the p value for the respective parameter was 
statistically significant (p < 0.05).   
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Figure 3.2. AT Specific Regulation of DUSP4 and DUSP9 and Inflammatory 
Mediators during the Development of Obesity under Conditions of Genetic and 
Diet-induced Obesity. AT was harvested and RNA prepared from A) 6-wk-old and B) 
10-wk-old male B6.V-LepOb/J (ob/ob) mice and their lean littermates, along with male 
C57B116J C) 18-wk-old and D) 24-wk-old DIO mice and their lean controls. Relative 
DUSP mRNA abundance was measured via qRT-PCR and statistical significance 
determined student’s t-test (p<0.05). All data were normalized to 18S rRNA and 
expressed relative to lean littermates. 
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Figure 3.3. Biphasic Induction of DUSP4 during Adipocyte Differentiation. 
Preadipocytes were stimulated with MDI and cell lysates harvested during A) early and 
C) late differentiation at indicated times and protein expression of DUSP4 along with 
bisphosphorylated ERK and PPARanalyzed via immunoblotting. In addition, total 
RNA was harvested during B) early and D) late adipocyte differentiation prior to mRNA 
analysis of DUSP4 using qRT-PCR. Data were normalized to 18S rRNA and expressed 
as relative differences compared to untreated preadipocytes (d0). 
A 
D C 
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Figure 3.4. DUSP4 Induction in Response to ERK Activation and MAPKs 
Phosphorylation Status during Adipocyte Differentiation. A) Preadipocytes were 
stimulated with MDI in the presence or absence of individual MAPKs inhibitors. Cell 
lysates were harvested at indicated times and protein expression of DUSP4 along with 
bisphosphorylated ERK and PPARanalyzed via immunoblotting. M: MDI only; E: 
U0126+MDI; J: SP600125 +MDI; P: SB203580+MDI. B) Preadipocytes were 
stimulated with MDI and cell lysates harvested over time prior to immunoblot analysis 
of bisphosphorylated ERK, JNK, and p38 as well as PPAR 
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Figure 3.5. DUSP4 is Suppressed in PAs and ADs in Response to TNF-α. Total 
RNA was collected from PAs and ADs stimulated in parallel with 100pM TNF-α over 
time and gene expression of DUSP4 measured via qRT-PCR. All data were normalized 
to 18S rRNA and expressed relative to untreated cells. Genes were considered 
suppressed when fell below a 0.5 criterion indicated by the dotted line on the graph. 
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Figure 3.6. ERK-independent DUSP4 Induction during Adipocyte Differentiation 
is not Mediated by PPAR and is Specific to Differentiation. A) 3T3-L1 
preadipocytes were stimulated with MDI in the presence or absence of Troglitazone 
(Trog), B) NIH 3T3 cells were treated with MDI, and C) F442A cells were induced to 
differentiation with insulin in the presence or absence of Trog. Cell lysates were 
harvested at indicated times during adipocyte differentiation and immunoblotted for 
dusp4 and PPARas well as -tubulin. 
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Figure 3.7. DUSP4 Knockdown does not Suppress Adipocyte Differentiation. 
DUSP4 knockdown or control 3T3-L1 PAs were stimulated to differentiation with MDI. 
A) Total RNA was collected and gene expression of DUSP4 measured via qRT-PCR. 
All data were normalized to 18S rRNA and expressed relative to untreated cells (d0). 
B) Cell morphology and lipid accumulation was assessed with DUSP4 knockdown and 
control 3T3-L1 cells during adipocyte differentiation using phase contrast microscopy 
at 10x magnitude. 
 
 
101 
 
Figure 3.8. Proposed Working Model for Role of DUSP4 during Adipocyte 
Differentiation. (see text for details) 
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CHAPTER IV 
EPILOGUE 
 
 
Data presented in this dissertation represented the first empirical evidence 
demonstrating the regulatory mechanisms and potential physiological functions of 
MAPK-specific DUSP4 in 3T3-L1 adipocytes. Moreover, findings from the previous 
chapters along with other observations made by our lab generated additional questions 
for future investigation. These preliminary findings and potential areas of focus will be 
discussed in detail in this chapter.  
Our findings presented in Chapter II of this dissertation collectively 
demonstrated that DUSP4 was only upregulated in response to strong and sustained 
ERK activation. Besides inducing the expression of DUSP4, ERK activation also directly 
increased DUSP4 protein stability. In addition, we observed that induction of DUSP4 was 
highly correlated with the inhibition of ERK phosphorylation in the nucleus and DUSP4 
could co-immunoprecipitate with ERK, suggesting a role for DUSP4 in spatiotemporal 
regulation of ERK activity. As we found unique regulation and function of DUSP4 from 
Chapter II, we next investigated the regulation and role of DUSP4 in metabolically active 
insulin responsive tissues under conditions of obesity, as well as during 3T3-L1 
adipogenesis. Data presented in Chapter III demonstrated that DUSP4 was abundantly 
expressed in white adipose tissue (WAT) and suppressed under conditions of genetic
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and diet-induced obesity, which is associated with WAT inflammation and IR. 
Furthermore, we observed an ERK-independent DUSP4 induction during late-stage 
adipocyte differentiation and this induction was significantly suppressed by TNF-α 
treatment. However, DUSP4 knockdown did not suppress adipocyte differentiation, 
suggesting that this phosphatase does not play a direct role in normal adipogenesis. 
Collectively, data presented in this dissertation provide regulatory mechanisms that 
have never been studied regarding the novel role of DUSP4 with the adipocyte lineage 
that potentially links obesity with metabolic inflammatory diseases. 
Data presented in this dissertation highlight regulatory mechanisms of DUSP4 in 
adipocytes in response to specific MAPK agonists (Ch.2). Although studies have reported 
that DUSP4 can be upregulated in response to growth factors, oncogenes, oxidative 
stress and UV radiation[1, 2], all of which are also known as MAPK activators, the 
precise mechanism regarding DUSP4 regulation in adipocytes remains unsolved.  Our 
preliminary findings showed that DUSP4 was markedly up-regulated only in response to 
strong and sustained ERK activation, while transient ERK activation had no effect on 
DUSP4 upregulation. On the other hand, activation of JNK or p38, regardless of the 
signal duration or magnitude, did not induce DUSP4 expression, suggesting that the ERK 
pathway is the primary signaling cascade responsible for DUSP4 induction. Moreover, 
early evidence has shown that upon extracellular stimulation, DUSP4 exhibited a relative 
late phase induction when compared to DUSP1, a prototypical member of the nuclear 
inducible DUSPs initially identified as an immediate early gene [3]. Consistent with the 
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report, we further demonstrated that DUSP1 mRNA level peaked 30 min post-PMA 
while expression of DUSP4 was maximally induced at 2 hrs, suggesting potential 
coordinated action among nuclear DUSPs in controlling ERK activity. As ERK is only a 
kinase that phosphorylates numerous transcription factors, future studies identifying 
potential transcription factor(s) involved in DUSP4 gene expression would enhance our 
understanding of DUSP4 regulation in adipocytes by MAPK signaling cascades. 
Activated ERK has been reported to phosphorylate DUSP4 and stabilize this 
protein form degradation by proteasome in other cell types [4-6]. We next examined 
the role of ERK on DUSP4 protein stability in adipocytes (Ch.2). Using cycloheximide to 
inhibit additional protein synthesis, we observed that DUSP4 protein was very stable 
throughout the experiment period as long as ERK remained activated. However, we 
showed that DUSP4 protein half-life markedly decreased when ERK activation was 
inhibited by U0126, indicating that activation of ERK is essential for DUSP4 protein 
stability. Moreover, blockade of proteasome activity by epoxomicin partially restored 
the loss of DUSP4 protein in response to suppressed ERK activation, suggesting DUSP4 
protein degradation is partially mediated by proteasome. Therefore, future 
investigations examining specific phosphorylation site(s) on DUSP4 as well as potential 
mechanisms involved in DUSP4 protein degradation will increase our understanding of 
DUSP4 regulation in adipocytes. 
Data highlighted in Ch.2 further demonstrated that the accumulation of DUSP4 
in the nucleus correlated with the inhibition of nuclear phospho-ERK signal while 
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cytosolic phospho-ERK remain elevated. In addition, studies have demonstrated that 
besides dephosphorylating activated ERK, several DUSPs can serve as anchors that 
retains ERK within certain cellular compartments [7-9]. As the role for DUSP4 in 
regulation of ERK has not been fully elucidated in adipocytes, we examined the 
association between DUSP4 and ERK. Using aldehyde-activated agarose beads coupled 
with anti-DUSP4 antibody, we could co-immunoprecipitate (Co-IP) ERK with DUSP4 only 
when this phosphatase was expressed. However, when using anti-ERK antibody, DUSP4 
could not co-immunoprecipitated with ERK under the same treatment condition. One 
possible explanation is that because DUSP4 is exclusively localized to the nuclear 
compartment, pulling down sufficient amount of DUSP4 protein allows us to detect 
relatively strong ERK signal when protein-protein interactions between these two 
proteins exist. In contrast, as the anti-ERK antibody detects both phosphorylated and 
dephosphorylate forms of ERK protein in the whole cell lysate, ERK-DUSP4 complexes 
are very likely to be mixed with other single ERK molecules. Even if we pull down 
sufficient amount of ERK protein, those that were coupled with DUSP4 may be very 
limited, therefore affecting the signal strength of DUSP4 that can be detected. These 
data suggested a potential role for DUSP4 in retaining ERK and consequently inhibiting 
ERK reactivation in the nucleus as prolonged activation of ERK in the nucleus may lead 
to adverse effects in quiescent cells.  
Observations presented above highlight future studies involving regulatory 
mechanisms of DUSP4 in adipocytes. In this dissertation, we demonstrated the 
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regulation of DUSP4 under conditions of obesity, as well as a role for DUSP4 in adipocyte 
differentiation (Ch.3). Preliminary findings from our lab demonstrated that DUSP4 was 
abundantly expressed in WAT of lean mice. Using genetic-induced (GIO) and diet-
induced (DIO) mouse models of obesity, we showed that DUSP4 was only induced 
during early stage GIO with no elevated levels of TNF-α. Expression of DUSP4 was 
markedly suppressed during the sequential stage of GIO with TNFα-mediated 
inflammation. During early stage DIO, DUSP4 induction was not observed as TNF-α level 
was already elevated. DUSP4 expression was further suppressed at the sequential stage 
of DIO correlating with the progressive increase in TNF-α. Interestingly, observations 
from our lab further showed that DUSP9 was upregulated in WAT of GIO and DIO mice 
and TNF-α-mediated inflammation did not affect its expression, suggesting divergent 
regulation for members of DUSPs under conditions of obesity. As others have already 
demonstrated a protective role for DUSP9 against inflammation that couples obesity to 
IR [10], future examination of DUSP4 towards obesity-mediated inflammation would 
expand our knowledge regarding its regulatory action in WAT under conditions of 
obesity. 
We also presented data demonstrating that mRNA and protein expression of 
DUSP4 was markedly induced during late stages of adipocyte differentiation, which was 
consistent with the observation on DUSP4 induction during early stage GIO. This late 
phase induction is independent of the ERK pathway as ERK phosphorylation status 
remained at basal condition throughout the course of differentiation. Subsequently, we 
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demonstrated that expression of DUSP4 was significantly suppressed in preadipocytes 
(PAs) and adipocytes (ADs) in the presence of TNF-α. Our findings further demonstrated 
that late phase DUSP4 induction correlated with PPARγ induction during adipocyte 
differentiation. PPARγ is a nuclear transcription factor highly expressed in AT and 
considered a master regulator of adipogenesis. Activation of PPARγ initiates 
transcription of genes that regulate lipid and glucose metabolism in adipocytes [11-13]. 
Early evidence revealed that phosphorylation of PPARγ by abnormal MAPKs activity 
affects its transcriptional activity during adipogenesis [13-15], leading to decreased 
triglyceride storage, increased fatty acids release and IR [16]. Based on these 
preliminary findings, we hypothesize that under normal physiological conditions, DUSP4 
precisely controls MAPK activation critical for adipogenesis. However, as obesity 
progressively develops, inflammation-mediated suppression of DUSP4 may interrupt the 
balance between activation and inactivation of MAPKs, leading to impaired PPARγ 
activity and adipocyte dysfunctions. Finally, we demonstrated that DUSP4 knockdown 
did not suppress adipocyte differentiation, suggesting that DUSP4 does not directly 
participate in the process of differentiation, but rather modulates MAPK 
phosphorylation status so that differentiation can proceed normally. Considering that 
TNF-α suppresses the expression of DUSP4, gain-of-function study would be a more 
promising approach to help us delineate the role of DUSP4 towards inflammation-
mediated abnormal MAPK activity during adipogenesis. 
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Data presented in Chapter II and III significantly contribute to the limited body of 
knowledge regarding regulation and function of DUSP4 in adipocytes. Use of the murine 
3T3-L1 cell line provided an excellent model to study and characterize DUSP4, as this cell 
line does not contain other cell types (e.g. macrophages, endothelial cells, nerve cells, 
etc.) Such conditions allow us to delineate MAPK signaling events in a homogenous 
population of cells. Moreover, our findings have led to ample questions for future 
studies related to DUSP4 in adipocytes. It is expected that continued examination of 
DUSP4 will provide research scientists with a better understanding of signaling networks 
involved in obesity, inflammation, and IR potentially, therefore providing new 
therapeutic targets for the treatment of obesity-associated metabolic dysfunctions.
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